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Summary 
 
Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease, which 
affects around three million people worldwide and is the main cause of disability in 
young adults in the US and western Europe. It is characterised by lymphocytic 
infiltration into the central nervous system (CNS) and destruction of 
oligodendrocytes, followed by neuronal cell death. The definite cause of the 
disease is unknown, but most likely consists of an interplay of genetic and 
environmental factors. Epidemiological studies have demonstrated that the 
incidence and severity of MS is inversely correlated with exposure to UV light. 
Recent evidence has raised doubt for the UV-mediated production of vitamin D as 
the sole responsible factor for the protective effect of UV light. The aryl 
hydrocarbon receptor (AhR) is a key regulator of immune responses in neuro-
inflammation and can be activated by UV photoproducts of tryptophan. We 
therefore investigated the role of UVB-mediated AhR activation in experimental 
autoimmune encephalomyelitis, the mouse model of MS. Animals lacking the AhR 
did not get any benefit from UVB irradiation, while the irradiation of specific AhR-
reporter mice showed an increased bioluminescence signal in the skin, which 
reflected an AhR activation upon UV treatment. Furthermore, we identified inosine 
as a potent activator of the AhR accumulating in skin of irradiated mice. Antigen 
presenting cells homed from the skin to the draining lymph nodes due to UVB 
irradiation and AhR activation, where they were able to induce regulatory T-cells, 
the so-called UV-Tregs. In addition to its effects on the immune system, the AhR is 
widely studied as an important mediator of toxicity for xenobiotics. While we could 
not prove that the immunosuppressive effect of Teriflunomide, a newly approved 
drug for MS treatment, could be in part mediated by AhR activation, we identified 
the AhR as the main mediator of its gastrointestinal toxicity. AhR deficient animals 
treated with Teriflunomide died due to gastroenteritis, intestinal bleeding and liver 
toxicity. Our data showed that, in the mouse model of MS, the AhR is a key 
molecule in mediating the immunosuppressive effect of UVB light and the 
metabolisation of the MS drug Teriflunomide. Pharmacological targeting of the 
AhR could enhance the beneficial effects of UVB light. Genetic polymorphisms of 
the AhR in MS patients could explain the increased side effects of Teriflunomide. 
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Zusammenfassung 
 
Multiple Sklerose (MS) ist eine Autoimmun- und neurodegenerative Erkrankung, 
von der circa drei Millionen Menschen weltweit betroffen sind und die 
Hauptursache von Behinderungen bei jungen Erwachsenen in den USA und 
Europa ist. MS ist charakterisiert durch lymphatische Infiltrationen ins zentrale 
Nervensystem (ZNS) und die Zerstörung von Oligodendrozyten, gefolgt von 
neuronalem Zelltod. Die Ursache dieser Krankheit ist unbekannt, beinhaltet aber 
höchstwahrscheinlich das Zusammenspiel genetischer und umweltbedingter 
Faktoren. Epidemiologische Studien haben gezeigt, dass die Inzidenz und 
Schwere der MS invers mit der Exposition gegenüber UV-Licht ist. Neueste 
Evidenzen haben Zweifel an der UV-vermittelten Vitamin D Produktion als 
alleiniger verantwortlicher Faktor für den protektiven Effekt von UV-Licht geweckt. 
Der Arylhydrokarbon-Rezeptor (AhR) ist ein Schlüsselregulator der 
Immunantworten während Neuroinflammation und kann durch Tryptophanderivate, 
die durch UV-Licht entstehen, aktiviert werden. Daher haben wir die Rolle der 
UVB-vermittelten AhR-Aktivierung in der Experimentellen Autoimmun-
Encephalomyelitis, dem Mausmodell der MS, untersucht. AhR defiziente Tiere 
profitierten nicht von UVB-Bestrahlung, während die Bestrahlung von spezifischen 
AhR-Reporter-Mäusen zu erhöhter Biolumineszenz in der Haut, was die AhR-
Aktivierung durch UV-Behandlung widerspiegelt. Weiterhin haben wir Inosin als 
einen potenten AhR-Aktivator identifiziert, der in der Haut bestrahlter Mäuse 
akkumulierte. Antigen-präsentierende Zellen migrierten aufgrund von UVB-
Bestrahlung und AhR Aktivierung aus der Haut zu drainierenden Lymphknoten , 
wo sie regulatorische T-Zellen induzierten, sogenannte UV-Tregs. Zusätzlich zu 
diesen Effekten auf das Immunsystem wird der AhR weitgehend als ein wichtiger 
Mediator der Toxizität von Xenobiotika untersucht. Wir konnten zeigen, dass die 
immunsuppresiven Effekte von Teriflunomid, einer neuen zugelassenen 
Medikation für MS, nicht durch die AhR-Aktivierung vermittelt werden; allerdings 
identifizierten wir den AhR als den Hauptmediator der gastrointestinalen Toxizität 
von Teriflunomid. AhR defiziente Tiere, die mit Teriflunomid behandelt wurden, 
entwickelten tötliche Gastroenteritis, intestinale Blutungen und Lebertoxizität. 
10 
 
Unsere Daten zeigen, dass der AhR im Mausmodell der MS ein Schlüsselmolekül 
ist, das die immunsuppressiven Effekte von UVB-Licht sowie den Metabolismus 
des zugelassenen MS-Medikaments Teriflunomid vermittelt. Pharmakologisches 
Abzielen auf den AhR könnte die günstigen Effekte von UVB-Licht verstärken. 
Genetische Polymorphismen des AhR in MS-Patienten könnten die erhöhten 
Nebenwirkungen von Teriflunomid erklären. 
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1. Introduction 
 
1.1 Multiple sclerosis  
 
Multiple sclerosis (MS) is a chronic neuro-degenerative disease, described for the 
first time in 1868 by the French neurologist Dr. Jean-Martin Charcot . It occurs due 
to an abnormal response of the immune system against the central nervous 
system (CNS), where T cells and macrophages are attaching and destroying the 
myelin shields surrounding the nerves. Myelin is a lipids-rich substance that 
normally insulates the axons and helps speed nerve transmission but, once 
damaged, it forms a harder scar tissue (1), that distorts or interrupts nerve 
impulses from the brain and the spinal cord. This results in a wide variety of 
neurological symptoms, but it can also lead to cognitive and physical disability, 
with loss of muscle control, balance and vision (2). Fatigue occurs in 90% of 
patients and is the most common work-related disability associated with MS. More 
than 30% of MS patients have moderate-to severe spasticity, mostly in the legs. 
They often suffer of sensory disturbances, like paresthesias (numbness and 
tingling), dysesthesias (burning and “pins and needles”), diplopia, ataxia or vertigo 
(3). It can be a unilateral numbness affecting one leg, but it can also spread to the 
other leg and rises to the pelvis, abdomen, or thorax and even evolve in chronic 
neuropathic pain. Another common sign of MS is optic neuritis, highlighted by 
complete or partial loss of vision. Some organs can also be involved, causing for 
example bladder dysfunctions or sexual problems. 
Four disease courses have been identified among MS patients and each of them 
can be mild, moderate or severe. Relapsing-remitting MS (RRMS) is the most 
common form, where 85% of patients are initially diagnosed. It is characterized by 
specific neurologic attacks, so called relapses, followed by partial or complete 
recovery periods (remissions), during which there is a partial or even complete 
improvement of the symptoms and no apparent progression of the disease. During 
these inflammatory attacks, activated immune cells cause small, localized areas of 
damage and this induces MS symptoms like numbness, vision problems, spasticity 
or stiffness, bowel and bladder problems, and problems with cognition. Even if the  
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damage locations can vary a lot, magnetic resonance imaging scans (MRI) proved 
that RRMS patients tend to have more lesions on the brain. Secondary-
progressive MS (SPMS) usually follows the first course, since most of the people 
diagnosed as RRMS will reach this phase. Relapsing moments are becoming rarer 
and the disease progressively gets steadier, here the inflammatory process leaves 
space to the nerves damaging phase. The third course, the primary-progressive 
MS (PPMS), has not remitting phases anymore, but the worsening of neurologic 
functioning is continuous. In this course, that affects about 10% of patients, lesions 
are more on the spinal cord side and this usually corresponds to gradually 
worsening problems with walking and mobility. Progressive-relapsing MS (PRMS) 
is the least common of the four disease courses, characterized by progressing 
disease from the beginning and occasional exacerbations along the way. 
Sometimes a patient is initially diagnosed as PPMS and then the diagnosis can be 
modified when the first relapse occurs. Although this disease course is progressive 
from the outset, each person’s symptoms and rate of progression will be different. 
In order to make a proper diagnosis, focusing on the predictive value of the early 
clinical course of MS might not be enough. But it is also true that individuals are 
often diagnosed in early adulthood and therefore encounter a variety of common 
experiences that must be managed within the context of their chronic illness. Since 
there is not a specific diagnostic test for MS, the diagnosis is based on evidences 
and clinical findings obtained from magnetic resonance imaging (MRI) of the brain 
and examination of the cerebrospinal fluid (CSF). Three parameters are usually 
considered: the attack rate, the first inter-attack interval and the rate at which 
disability develops in the early years of the disease, referring to the chronic 
inflammation of the CNS, as determined by analysis of the CSF (3, 4) .  
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Figure 1.1. Multiple sclerosis in patients. A. comparison between an healthy axon and a damaged 
one, where myelin is destroyed and the nerve is exposed (http://www.mswatch.ca/en/learn-about-
MS/what-is-MS/the-central-nervous-system-and-MS.aspx). B. Curves representing the four disease 
courses found in MS patients: RRMS, SPMS, PPMS and PRMS (http://www.life-in-spite-of-
ms.com/stages-of-multiple-sclerosis.html). 
 
Up to now there is no known cure for MS and the only treatments available, so 
called disease modifying therapies (DMTs), are made for relapsing forms of MS, to 
prevent new attacks and disability. Acute cases can be treated with short courses 
of corticosteroids, which act rapidly with few adverse side effects. The same 
treatment can be used for acute exacerbations and to shorten the duration of MS 
attacks. The other FDA-approved therapeutic agents can reduce disease activity 
and progression in patients with relapsing forms of MS, including patients with 
secondary progressive MS who continue to have relapses. Most of them are 
immunomodulatory agents that retard the neurological damages, like interferon 
beta (IFN-β) or glatiramer acetate (copaxone). These two have been considered 
for a long time the main treatment options for RRMS, although they are only 
partially effective, reducing relapses by about 30% compared to placebo. Different 
interferon-based drugs have been developed, due to their natural functions as 
cytokines but, although some side effects, the main issue emerged during long 
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term treatment. In fact treatment with any IFNs can lead to the production of 
neutralizing antibodies (5). Furthermore, Shiriani and coworkers (6) did not find 
any significant effect on progression to long-term disability using IFN-β and this 
also opened the way for new compounds to prevent MS damages. In the last ten 
years many MS drugs became available, but what came more and more important 
is also the balance between benefits and possible side effects. Some examples 
are Mitoxantrone, a cytotoxic agent restricted to severe cases due to its cardiac 
toxicity and risk to develop secondary leukemia or Natlizumab, a monoclonal 
antibody effective in inhibiting T-cell infiltration in the brain, but also associated 
with potentially fatal multifocal leukoencephalopathy. The most recent compounds 
are focusing on the immune cell inactivation, some of them have been already 
used for other immune diseases and the ways of administration as well as the 
safety profile are important parameters to be considered. 
 
Among them, we focused our attention on TERIFLUNOMIDE, an oral daily drug 
treatment marketed by Sanofi and available on 7 or 14 mg film coated tablets. 
Teriflunomide (trade name Aubagio), is the active metabolite of the prodrug 
leflunomide (Arava®), which was approved in 1998 by the US FDA for the 
treatment of adults with rheumatoid arthritis (7). Also known as A77 1726, it was 
investigated in the Phase III clinical trial TEMSO, TENERE, TOWER, TERACLES 
and TOPICS as a medication for multiple sclerosis (1, 3, 8-10). The registration 
study was completed in July 2010, with positive results. The drug was approved by 
the FDA on September 13, 2012 and in the EU on August 26, 2013. Immune cell 
activation and proliferation, which are critical for the progression of autoimmune 
diseases such as MS, are dependent on de novo pyrimidine synthesis and 
extensive in vitro studies have shown that teriflunomide is a selective and 
reversible inhibitor of mitochondrial dihydroorotate dehydrogenase (DHODH), the 
key enzyme involved in this process (11, 12). The enzyme is noncompetitively and 
reversibly inhibited by teriflunomide with and IC50 of 1.3 µM in humans and 86 nM 
in rats .Teriflunomide reversibly arrests cells in the G1 phase of the cell cycle, 
inhibiting the de novo pyrimidine biosynthesis within the immune system.  This 
results in inhibition of cell proliferation and maturation, thereby preventing T cell 
and B cell clonal expansion and migration to the CNS as well as antibody 
production in vivo (12, 13). Mean plasma concentrations of Teriflunomide 
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resemble the ones detected for Leflunomide, when same dose is used. Peak 
plasma concentrations occur in 1 to 4 hours after oral administration and steady 
state occurs after approximately 3 months of treatment. Teriflunomide is highly 
bound to plasma proteins (> 99%), it undergoes minor metabolism, mainly 
mediated by hydrolysis, oxidation and conjugation reactions. The median half-life 
of TER is approximately 18-19 days and it is dose dependent, its elimination is 
mostly biliary dependent and metabolites are removed renally. The most common 
side effects of Aubagio® include abnormal liver test results, hair thinning or loss, 
diarrhea, flu, nausea, and burning or prickling feeling in the skin. Based on data in 
animal studies, there is also an increased risk of teratogenicity if teriflunomide is 
taken during pregnancy. Teriflunomide remains in the blood for a long time after 
stopping treatment, so this risk may continue for up to two years. Women of 
childbearing age must use reliable contraceptive methods and in case of 
pregnancy during the treatment, it is recommended the use of cholestyramine or 
activated charcoal to reduce the blood level of teriflunomide. Several other drugs 
are commercially available at the moment, but since they are just partially 
effective, further investigations have to be done. Furthermore, simple habits such 
as exercise, rest and healthful nutrition may relieve symptoms and promote a 
satisfactory quality of life. We also have to consider that, while the prognosis is 
difficult to predict and it depends on several factors, the life expectancy of MS 
patients is at the moment only 5 to 10 years lower than that of an unaffected 
population (14).  
 
1.2 MS risk factors  
 
MS is affecting about 2.5 million people worldwide and has been recognized 
across all ethnicities. It is more diffused in women than in men, with a female-male 
ratio of 3:1 that is significantly increasing during the last century and it usually 
occurs between 20 and 50 years of age with a peak around 30 years. The disease 
is thought to be triggered in a genetically susceptible individual by a combination 
of one or more environmental factors (15).  
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1.2.1 Genetic risks 
 
The concept of genetic inheritance and family risk is of considerable importance to 
patients with MS to help them make the necessary informed medical and personal 
decisions. Approximately 15% of patients with MS have a positive family history of 
the disease, and the overall age-adjusted risk in the general population is 
approximately 0.3%. Recurrence among monozygotic twins is approximately 35%, 
which reflects the degree of genetic contribution. The estimated risk to the siblings 
of a proband is 3–5%, increasing to 29.5% if one or both parents have MS. Risk to 
the offspring of a patient with MS is 2–3% and higher if both parents have MS 
(20%) (16, 17). If genes were solely responsible for determining who gets MS, an 
identical twin of someone with MS would have a 100% chance of developing the 
disease; the fact that the risk is only one in three demonstrates that a complex 
multifactorial aetiology, including interactions of genetic and environmental factors 
is likely. This  multifactorial aetiology is common to similar autoimmune diseases is 
typical, for example, rheumatoid arthritis or diabetes mellitus type I (18). Large-
scale genome-wide association studies have helped to identify several genes 
associated with disease susceptibility, the most important of which include HLA-
DRB1, IL7R (CD127), IL2R and SOCS1 (19-21). The association between MS and 
HLA was already described in 1970s and nowadays the associations between 
HLA-DR15 haplotype (the DRB1*1501 allele and the alleles with which it is in 
linkage disequilibrium: DQA1*0102, and DQB1*0602) and MS have been 
described throughout European and non-European populations with MS (22, 23). 
These polymorphic genes may work independently and/or interact with each other, 
and will exert a minor or moderate effect on the development of MS (16, 24). 
 
1.2.2 Environmental factors – sun exposure 
 
Epidemiological data show several interesting trends regarding MS and its 
distribution among different populations and ethnic groups. MS is more common 
among Caucasians and among people of Northern or Central European descent, 
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especially from Scotland or Scandinavia. By contrast, MS is less common among 
Hispanics, Asians, and in people of African descent. MS rarely occurs among 
some ethnic groups, such as Inuits, Aborigines, and Maoris. In the U.S. the 
prevalence of MS is higher in whites than in other racial groups. There have been 
also "epidemics" of MS, for example, the group of people living off the coast of 
Denmark after WWII, suggesting an environmental cause. Migrant studies further 
support the important influence of environmental factors in risk of MS. In a 
systematic review of such studies two consistent patterns were apparent: migrants 
moving from a region of high MS risk to one of lower risk had a lower-than-
expected MS prevalence, particularly when migration occurred before age 15 
years; migrants moving from an area of lower risk to one of higher risk tended to 
retain the lower MS risk of their country of origin, with no clear age-at-migration 
effect (25, 26). This relationship is believed to be related to sunlight or UV light 
exposure. 
 
Figure 1.2. World distribution of MS patients. Adapted from a MSIF/WHO Study, published by BBC 
in September 2008. 
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In fact MS is a disease of temperate climates, its prevalence increases with 
distance from the equator for both hemispheres. Furthermore, this hypothesis is 
supported by different studies, where the average annual hours of sunlight 
exposure in an individual’s place of birth is inversely correlated with MS 
development or where individuals with the highest residential and occupational 
solar exposure have the lowest rate of MS incidence (27, 28).  
The sun emits a wide range of electromagnetic radiation, including UV (29) (100–
400 nm), visible (400–800 nm) and infrared (> 800 nm) radiation. Exposure to 
UVR has profound effects on human health, since it can cause direct damage to 
DNA and this is a leading cause of skin carcinomas. UVR exposure induces 
immune suppression, via the inhibition of cell-mediated immunity through multiple 
mechanisms, thereby eliminating natural defense mechanisms against aberrant 
cell growth. Although its effects in skin cancer, UVR exposure has also beneficial 
effects on organ-specific autoimmune diseases, like in MS. Indeed, a recent study 
demonstrated that MS relapse rates are lower in the summer than in the winter, 
suggesting that decreased UV exposure may be a contributing factor in relapses 
(30).  
 
 
 
 
20 
 
             
 
 
 
Figure 1.3. Schematic representation of the sun spectrum and the different light intensities through 
the wavelength pattern. © Thomson Higher Education. 
 
 
Thus, although avoiding UVR exposure may reduce the risk of various skin 
cancers, it could inadvertently increase the risk of developing autoimmune 
diseases such as MS. UV irradiation is also stimulating the immune response by 
the production of vitamin D3 in the skin. The cholesterol derivative 7-
dehydrocholesterol is in fact converted by UVB in previtamin D, that goes through 
different steps in liver and kidney in order to become the active hormone 1α,25-
dihydroxyvitamin D3 [1,25(OH)2D3]. 
The classic biological function of 1,25(OH)2D3 is to maintain sufficient serum 
calcium and phosphorus levels for proper mineralization of bone and 
neuromuscular function. In 1970s, Goldberg also postulated a peculiar role of 
vitamin D3 in MS and this was for long time the only explanation considered for the 
geographical distribution. Nowadays there are still groups investigating vitamin D 
in MS and clinical trials running, but we know that there are also publications 
sustaining that vitamin D is not essential or at least not enough (27, 31, 32). 
 
1.2.3 Other potential factors 
 
Sun exposure is not the only factor taken into consideration for MS. There is 
growing evidence suggesting that hormones, including sex hormones, can affect 
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and be affected by the immune system. For example, both estrogen and 
progesterone, two important female sex hormones, may suppress some immune 
activity. During pregnancy, levels of these hormones are getting very high, which 
may help explain why pregnant women with MS usually have less disease activity. 
Testosterone, the primary male hormone, may also act as an immune response 
suppressor. The higher levels of testosterone in men may partially account for the 
fact that women with MS outnumber men with MS by 3 to 1 (33). 
Also smoking plays an important role in MS. Studies have shown that smoking 
increases a person’s risk of developing MS and is associated with more severe 
disease and more rapid disease progression (16). Fortunately, the evidence also 
suggests that stopping smoking, whether before or after the onset of MS, is 
associated with a slower progression of disability. 
In 2012 an international team led by U.C. Meier (34) proved  that the Epstein-Barr 
virus might also contribute to the brain inflammation that occurs in MS. White 
matter postmortem MS tissue and control tissue were analyzed by 
immunohistochemistry for the expression of the proinflammatory cytokine 
interferon α (IFNα) and for EBV by using EBV-encoded RNA (EBER) in situ 
hybridization. They found high levels of interferon alpha in active MS brain lesions, 
as well as neighboring immune B cells latently infected by Epstein-Barr virus, in 
the absence of active viral infection. These findings may point to a possible 
mechanism for how the virus might indirectly stimulate MS disease activity. 
 
1.3 Experimental Autoimmune Encephalomyelitis 
 
MS is a complex disease that, despite years of extensive research and the 
development of several partially effective treatments, still does not have an 
effective cure. Researchers are performing in vitro as well as in vivo studies to 
mimic the disease development in laboratories, but they have only limited access 
to MS tissue samples. For these reasons, animal models are needed to better 
understand the underlying mechanisms and to test new therapeutic approaches. 
One of the most extensively tool used is the animal model called Experimental 
Autoimmune Encephalomyelitis (EAE). EAE was described and discovered in 
1930s by Thomas M. Rivers, while trying to elucidate the etiology of neurological 
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complications that followed anti-rabies vaccinations. He performed his 
experiments in rhesus monkeys immunised with emulsions of normal sterile rabbit, 
in order to induce an inflammatory demyelinating disease in brains: 75% of the 
treated monkeys were showing myelin destruction with perivascular infiltrates in 
brains and spinal cords (7). Subsequently, EAE induction was performed using 
adjuvants added to brain emulsions, spinal cord homogenate, myelin preparations, 
or purified myelin proteins. Since then, EAE has been induced in a variety of 
mammal species, including mice, rats, guinea pigs, rabbits, goats, sheep, 
marmosets and primates CNS (35). In 1947 Wolf et al. documented that EAE 
resemble the human demyelinating diseases (36). EAE describes a chronic 
experimental demyelinating disease with an acute onset characterized by focal 
areas of inflammation as well as demyelination through the CNS (35). It is induced 
by subcutaneous injection of an adjuvant emulsified with a synthetic peptides 
derived from myelin proteins, like myelin oligodendrocyte glycoprotein (MOG), 
myelin basic protein (MBP) or proteolipid protein (PLP). There are also transgenic 
mice (2D2 TCR) that can develop EAE spontaneously or with minor doses of MOG 
(37), and EAE can also be induced by cell transfer from EAE donors to native 
recipients. The immunisation procedure leads to activation and expansion of 
peripheral antigen-specific T-cells, that pass the blood brain barrier (BBB), enter 
the CNS and encounter the specific myelin antigen. In general, encephalitogenic 
antigens are applied together with Bordetella pertussis toxin (PTox) and the 
complete Freund’s adjuvant (38), made by mixing the incomplete solution with 
Mycobacterium tuberculosis (CFA). In fact, the antigen is emulsified in the oil 
emulsion of CFA, that serves as a depot, providing slow release of both the 
antigen and the inactivated mycobacterium. The incidence and severity of the 
disease induced by immunisation is enhanced by the coinjection of PTox, that  
induces local antigen presentation via non-specific inflammatory reaction (39). The 
disruption of the BBB has been considered for long time the mechanism by which 
PTox facilitates the EAE induction (40), but recently the promotion of autoimmune 
Th1 / Th2 response seems to be a better interpretation for its usage (41).  
In order to address to this thesis hypotheses, the MOG induced EAE model has 
been used in C57BL\6J mice. Here below, a typical scoring curve, where mice are 
scored every day considering their disease stage. After an initial phase that follows 
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the first days post immunisation, the disease develops with a peak reached after 
approximately 14 days. There is then a remission phase, when mice are getting 
better, until they reach the chronic phase and their sickness stage is reaching a 
plateau. 
 
 
 
Figure 1.4. Schematic representation of a typical curve of MOG-induced EAE in C57BL/6 mice 
(http://hookelabs.com/products/EK-2110/).  
 
Studies involving EAE have had an important role in identifying and delineating 
several aspects of the MS biology: inflammation, immune surveillance and 
immune-mediated tissue injury. Moreover, this experimental model has directly 
lead to the development of three medications approved for multiple sclerosis, 
glatiramer acetate, mitoxantrone and natalizumab (42). On the other hand, EAE is 
not the perfect model for MS since numerous therapeutic approaches that showed 
promising results in EAE turned out to be either ineffective or in some cases 
harmful in MS. Therefore other models have been proposed such as Theiler’s 
Murine Encephalomyelitis Virus (TMEV) infection. TMEV was initially described in 
1934 by Max Theiler as a filterable agent that was a known cause for paralysis in 
mice, but not in monkeys. It is indeed a mouse enteric pathogen, that belongs to 
the single-stranded RNA picornaviruses, an extremely small viruses family. This 
virus can be highly virulent and cause even fatal encephalomyelitis, but the strains 
used for MS research are less virulent and the disease caused by these strains is 
either mono-or biphasic. The monophasic disease consists of a transient meningo-
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encephalo-myelitis, which reaches its peak in 7 days and last approximately 3 
weeks. The biphasic phase consists of  an initial monophasic phase followed by a 
chronic demyelinating stage, where most of the demyelinating lesions are in the 
spinal cord, similarly to EAE models (43). Unlike EAE, the disease is always 
chronic-progressive in susceptible mice and its pathology is more similar to human 
MS. With the advent of small animal MRI and MRS techniques, a growing number 
of investigators are trying to draw parallels between human MS and its rodent 
models. However, it has to be stated that there is no single animal model that can 
capture the entire spectrum of heterogeneity of human MS and its variety in 
clinical and radiological presentation. Appropriate animal models have to be 
selected depending on the specific research question, still considering the clearly 
existing limitations.  
 
1.4 The immune system in MS 
 
It is now generally accepted that the demyelination seen in MS is caused by an 
abnormal immune response mediated by T cells. Over the last 15 years, several 
studies have been done to investigate these cells and elucidate their role.   
 
1.4.1 The MS immune cells 
 
Until a few years ago, it was believed that CD4+  T helper type 1 (Th1) cells were 
the main effectors T cells responsible for the autoimmune inflammation. These 
cells are secreting interferon gamma (IFNγ) and have been found in brain lesions, 
in CSF and blood of MS patients as well as in EAE mice (44). More recent studies 
have highlighted an important pathogenic role in EAE for CD4+ T cells that secrete 
interleukin (IL)-17, so called TH17 (45). Therefore, it seems that there is a bipolar 
mechanism involved, where IFN-γ– and IL-17–producing T cell subsets are 
important for promoting EAE, while IL-10 is important for EAE negative regulation 
(46, 47). As the capacity to define subsets of immune cells has evolved, an 
increased number of other subsets have been implicated as mediators of immune 
regulation with different potential mechanisms of action. Even a brief search 
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through literature provides examples of groups that focused their attention on 
natural killer cells (NK) (48), others on IL-17-secreting γδ T cells (45) or microglia 
cells (49). In addition, a role for autoimmune MOG-specific CD8+ T cells 
responses have also been discussed (50). Still, immune cells have to overcome 
the BBB, in order to induce CNS inflammation. Whether BBB dysfunction 
precedes immune cell infiltration or is the consequence of perivascular leukocyte 
accumulation remains enigmatic, but leukocyte migration per se can also modify 
the BBB permeability and the access to CNS. Furthermore, immune cells express 
inflammatory cytokines, reactive oxygen species (ROS) and enzymes like matrix 
metalloproteinases (MMPs), that can facilitate their migration to the CNS by 
influencing BBB function (51).  
 
1.4.2 Skin cells 
 
The single appliance of antigens is not sufficient to promote an immune reaction, 
but specific cells have to be present and mediate the reactive cells activation. 
Dendritic cells (DCs) are “professional antigen presenting cells” that play an 
important role in promoting activation and differentiation of naïve T cells. These 
DCs are also involved in EAE response, where they activate encephalitogenic T 
cells and result in either induction or tolerance of the disease, depending on their 
own activation state and the antigen uptake mechanism (52). They are normally 
positioned as sentinels in the periphery, ready to migrate to secondary lymphoid 
organs, particularly lymph nodes, in case of foreign antigens invasion. There, they 
encounter with naive or central memory T cells and stimulate their activation. DCs 
are particularly important in this thesis context, due to their ability of promoting 
and/or repressing immune reactions depending on the local conditions (53, 54). 
The skin immune system, as first barrier against external antigens, relies on a rich 
network of professional antigen-presenting DCs that populate the epidermis and 
the dermis: Langerhans cells (LCs), macrophages, mast cells and γδ T cells. 
 
 
26 
 
 
 
Figure 1.5. A schematic view of the different cell types populating the skin (55).  
 
LCs got their name from Paul Langerhans, who was the first to report the 
presence of dendritic, non-pigmentary cells in the epidermis, regarded as intra-
epidermal receptors for extracutaneous signals of the nervous system. These cells 
remained an enigma to dermatologists for over a century until the recognition that 
LCs are leukocytes that are derived from the bone marrow and are the DC 
population found in the epidermis (56). They are characterized by distinct 
endocytic vesicles, termed Birbeck granules, surface markers like CD207 
(Langerin) and the presence of the epithelial cell adhesion molecule (EpCAM; 
CD326). The relative contributions of Langerhans cells and dermal dendritic cells 
in antigen uptake have been discussed for a long time, but studies in mice that 
exhibits Langerhans deficiencies helped to clarify their role. What has been clearly 
shown is that both of them can traffic to lymph nodes through afferent lymphatic 
vessels and their uptake capacity  are crucial for the execution of their functions 
(57, 58). Other innate cells, such as mast cells and macrophages, also populate 
the dermis and respond to pathogens by secreting proteases and inflammatory 
cytokines and chemokines. In addition to the classical αβ T cells, the dermis also 
have γδ T cells, which are important for the macrophages recruitment during 
inflammation and for the keratinocytes survival (59).  
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1.5 Tryptophan and the aryl hydrocarbon receptor 
 
The immune response can be regulated in different ways and in recent years 
tryptophan metabolism has received increasing attention as a potent 
immunosuppressive mechanism involved in the maintenance of immunological 
tolerance. L-tryptophan (Trp) is an essential amino acid that serves as a building 
block for proteins and neurotransmitters synthesis. Trp can only be synthesized by 
plants and microorganisms, therefore all the other organisms, that do not possess 
the enzymatic machinery to synthesize it from simpler molecules, have to assume 
it via diet. In the CNS, Trp is required for serotonin production, in pineal glands for 
the antioxidant melatonin and it is also involved in oxidoreductase reactions, with 
the synthesis of the cellular cofactor Nicotinamide adenine dinucleotide (NAD+) as 
main product (60). Originally, the effects of Trp in modulating the immune system 
have been thought to be mediated solely by its depletion. In fact, local depletion of 
Trp results in starvation of the surrounding cells, which leads to the activation of 
the integrated stress response (ISR) pathway via the  general control non-
depressible kinase 2 (GCN2), causing cell cycle arrest and anergy of T-
lymphocytes (61). Recent studies also focused on the Trp accumulation and 
showed that Trp can modulate the immune system via its metabolites. The 
enzymes that break down tryptophan through this pathway are found in numerous 
cell types, including cells of the immune system. Some of these enzymes are 
induced by immune activation, including the rate-limiting enzyme present in 
macrophages and dendritic cells, indoleamine 2,3-dioxygenase (IDO). IDO has 
been implicated in maternal tolerance towards allogeneic concepti, controlling 
autoimmune diseases and chronic infection, as well as promoting tumour immune 
escape (62-64). Two theories have been proposed to explain how tryptophan 
catabolism facilitates tolerance. One theory posits that tryptophan breakdown 
suppresses T cell proliferation by dramatically reducing the supply of this critical 
amino acid. The other theory postulates that the downstream metabolites of 
tryptophan catabolism act to suppress certain immune cells, probably by pro-
apoptotic mechanisms (60, 65).  
Several of the Trp metabolites have been demonstrated to bind, activate and 
mediate immune-modulation via the aryl hydrocarbon receptor (AhR). This 
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receptor, best known for mediating the response to xenobiotic and toxins such as 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), belongs to the bHLH/PAS family of 
transcription factors. It is normally localized in the cytosol, forming a multiprotein 
complex with two heat shock protein 90 chaperones (hsp90), a small protein (p23) 
and an immunophilin-like protein termed X-Associated Protein (XAP2). Upon 
binding with specific ligands, the complex dissociates and AhR migrates into 
nucleus. There, it forms an heterodimeric complex with the AhR Nucleus 
Translocating protein (ARNT), which binds to dioxin responsive elements (DRE or 
XRE) present in the upstream regulatory region of target genes and induces gene 
expression. The target genes identified include members of the cytocrome P450 
family, like CYP1A1, as well as the Ahr repressor (AhRR), which acts as 
competitor of ARNT and regulates therefore the entire process. 
 
Figure 1.6. Schematic representation of the AhR activation mechanism (The aryl hydrocarbon 
receptor (AhR) in the regulation of cell–cell contact and tumor growth – Oxford University Press). 
 
In the EAE context, it has been shown that the disease course can develop in 
different ways, depending on which ligand binds the AhR and consequently which 
kind of immune response is triggered. Interestingly, this twofold ligand-dependent 
mechanism can lead to an IL-17 upregulation, shifting the balance to a worse EAE 
state, or can expand the Treg population, inducing IL-10 and preventing EAE (66-
68). Due to its promiscuous binding site, structurally diverse synthetic and 
naturally ligands can bind the AhR. Among the natural ligands considered, the 6-
formylindolo[3,2-b]carbazole (FICZ) has been widely studied in vitro by Rannug 
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group (69). FICZ is a photoproduct of tryptophan with high affinity ligand for the 
AhR, is generated by UV light and implicated in the differentiation of DCs and 
CD4+ T cells. The key question, whether enough Trp metabolites can be produced 
in vivo in order to activate the AhR and modulate cellular function, remains 
unanswered. Generation of knockout mice lacking the AhR (AhR-/-) opened the 
way to further investigations in different fields (70, 71). 
 
Figure 1.7. Revised schema of the TH17 vs. Treg balance in the autoimmune response. 
(Immunology: T cells hang in the balance.  Emily A. Stevens & Christopher A. Bradfield). 
 
 
1.6 Aim of this thesis 
 
This work has been divided in two parts related to the investigation of the Aryl 
hydrocarbon receptor (AhR) and to its functions in a Experimental Autoimmune 
Encephalomyelitis context. Part 1 focuses on the beneficial effects of UVB 
irradiation in EAE. The aim of this project was to investigate the immunological 
mechanism behind the delayed onset of the disease observed in wt mice. 
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Following the hypothesis of an AhR involvement, we analysed the skin, as the first 
immunological compartment influenced by UVB. First, we wanted to identify the 
metabolites produced during the irradiation and possibly able to activate the AhR. 
We also focused our attention on the key cell populations involved, followed them 
during their migratory process to the lymphatic organs and analysed their 
interaction with other immune cells. The AhR-mediated activation of a specific T-
cell population could explain the different courses of the disease observed in the 
mice. Finally, microarray analyses were also performed, to obtain an overview of 
the pathways involved in the UVB response. 
Part 2 focuses on the response to the treatment of a newly approved MS drug, 
Teriflunomide (TER). The main purpose of this study was to investigate a possible 
interaction between AhR and TER, in order to gain information regarding the 
mechanism of action of this drug. AhR-proficient and -deficient mice were 
compared in their drug-response and lack of the AhR-induced morbidity and 
mortality of mice treated with TER. Further analyses were then necessary, to 
better understand the cause of death and the role of the AhR in this response. 
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2. Materials and methods 
 
2.1. Reagents and media 
 
Proliferation media was prepared in laboratory adding 10% FBS, 100 U/ml 
penicillin and 100 μg/ml streptomycin, 25 mM Hepes, 1 mM Sodium Pyruvate 
Solution, 0.1 mM Non-Essential amino acids solution and 5 x 10 M 2-
mercaptoethanol to RPMI-1640 with 2 mM L-glutamine. Staining buffer for Flow 
Cytometry was prepared in laboratory adding 3% FBS and 2 mM EDTA to PBS. 
All the components were purchased by PAA Laboratories (Pasching, Austria), 
while FBS was purchased by Thermo Fisher Scientific Inc., Waltham, MA, USA. 
Tetrachlordibenzodioxin (TCDD) was kindly provided by D. Schrenk 
(Kaiserslautern, Germany). StayBrite D-Luciferin and FICZ were purchased by 
Enzo Life Sciences (Lausen, Switzerland). L-Tryptophan, FITC powder, Acetone 
and Dibutylpftalate were purchased by Sigma-Aldrich (Saint Louis, MO, USA). 
 
2.2. Animals  
 
Female between 7 and 9 weeks old C57BL/6J WT mice were purchased from 
Charles River Laboratory (Sulzfeld, Germany). Albino-Bl6 (B6(Cg)-Tyrc-2J/J) and 
AhR-/- mice (B6;129-Ahrtm1Bra/J) were initially purchased from the Jackson 
Laboratories (Sulzfeld, Germany) and were bred and maintained in the DKFZ 
animal facility. As homozygous AhR-/- female mice are infertile, homozygous 
males were bred with hemizygous females. A new reporter mouse strain 
(DRE_Luc) was created in our lab to study the AhR activation. DRE-reporter mice 
were generated by randomly inserting 12 repeated DRE sites into the genomic 
mouse DNA upstream of a click beetle red luciferase and an mCherry 
fluorochrome, separated by a T2A site. Several DRE sites from the literature were 
tested in cell cultures for lowest background and highest activation levels upon 
stimulation with TCDD 10 nM. The sequence GATCGCCGGGTTTGCGTGCGAT 
(underlined: core recognition sequence of the AhR), repeated 12 fold, proved to be 
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the most efficient reporter construct (72, 73). The construct was amplified in E. 
coli, then linearized by restriction enzyme digestion and inserted into cells by y 
pronuclear DNA microinjection, carried out by the Interfacultary Biomedical Faculty 
(IBF), University of Heidelberg, Germany. Transgenic animals were detected using 
standard PCR from tail biopsies (β2-Microglobulin and mCherry – Table 1). 
Offspring of the first litter was tested for responsiveness to TCDD and the brightest 
mouse strain was chosen for further breeding and experiments. Mice were 
crossed to albino-Bl6 mice (B6(Cg)-Tyrc-2J/J) to obtain white transgenic animals 
suitable for detection of bioluminescence without shaving. The AhR and the 
DRE_Luc litters were genotyped from tail biopsies according to standard 
protocols. An Applied Biosystems 2720 Thermal Cycler was used to perform PCR 
reaction: as suggested by the Jackson laboratory, specific primers were used 
(listed in Table1) and protocol was adapted using Taq DNA Polymerase kit 
(Qiagen, Hilden, Germany). Samples were then loaded on 1% agarose gel, results 
were acquired using UV-Transluminator (INTAS Science Imaging, Göttingen, 
Germany) and listed in Tierbase software. All mice were housed at the DKFZ 
animal facility under specific pathogen-free conditions and exposed to 12-h light-
dark cycles. WT control mice were age- and sex matched to AhR-/- mice. All 
animal work was performed in accordance with the German animal protection law 
under the permission of the local authorities in Heidelberg and Karlsruhe. 
 
  AhR KO 443 GGATTTGACTTAATTCCTTCAGC 
            AhR -/- mice AhR KO 444 TCTTGGGCTCGATCTTGTGTCAG 
  AhR KO 8162 TGGATGTGGAATGTGTGCGAG 
    mCherry fwd ACCCAGACCGCCAAGCTGAAGGT 
           DRE_Luc mice mCherry rev CTCGTTGTGGGAGGTGATGTCCA 
  ß2-microgl fwd CACCGGAGAATGGGAAGCCGAA 
  ß2-microgl rev TCCACACAGATGGAGCGTCCAG 
 
Table 1. Primers used for genotyping AhR-/- and DRE_Luc mice. 
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2.3. UV irradiation procedure 
 
Following what described by Becklund (27), we built a UV irradiation system for 
our experiments. The machine consisted of a box made of trespa, a laminate 
material used for cladding, a movable plate done with the same material and 2 
plexiglas protecting panels, 6 mm thick. In the upper part of the box, four lamps 
UVB Broadband TL 20W / 12 (Philips, Amsterdam, Netherlands) were inserted in 
an housing steel luminary, they were emitting a broad band of UVR from 280 to 
360 nm, where approximately 65% of the output was in the UVB range (290–320 
nm). The surface area was approximately 720 x 481 mm and a sensor on the front 
door regulated the activation of the irradiation flux. The main switch was on the 
machine roof and a radiometer equipped with a 302-nm sensor was used to 
monitor the radiance (W/m2) and the radiant exposure (J/m2). The entire system 
was built in collaboration with LAT - Labor- und Analysen-Technik GmbH 
(Garbsen, Germany), lamps were purchased by Waldmann GmbH (Villingen-
Schwenningen, Germany) and a Waldmann sensor was kindly borrowed by the 
group of Prof. Rösl (ATV / DKFZ Heidelberg). 
 
 
Figure 2.1. Schematic representation and final picture of the UV machine built for mice irradiation 
experiment.  
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Mice from the control and UV-treated groups were shaved with electric clippers 1 
day before initiating UV therapy. UV-treated mice were irradiated in a specially 
designed 6-chamber Plexiglas cage to prevent mice from sheltering each other 
from the UVR. Because the UVB output was unequal in the different chambers, 
mice were rotated through the different chambers on successive days. They were 
irradiated starting from one week before immunisation every other day for 13 min 
(2.5 kJ/m2) at a distance of 40 cm from the UV source. Same UVB dose and 
timing was kept for the whole duration of the experiment. Mice from control group 
also received a sham treatment and Bepanthen (Bepanthen®, Bayer Vital GmbH, 
Leverkusen, Germany) was applied on their eyes in order to protect them from UV 
light. 
 
2.4. Induction of EAE  
 
Myelin oligodendrocyte glycoprotein peptide (MOG35–55) 
(MEVGWYRSPFSRVVHLYRNGK) was purchased from GenScript USA Inc. The 
MOG35–55 peptide was resuspended in sterile PBS to a concentration of 4 mg/ml, 
then emulsified with an equivalent volume of complete Freund’s adjuvant (CFA) 
supplemented with 5 mg/ml inactivated Mycobacterium tuberculosis H37Ra 
(DIFCO Laboratories, Detroit, MI, USA). EAE was induced in 8-week-old 
C57BL/6J female mice as described elsewhere (27). Briefly, mice were injected 
s.c. with 50 µl of emulsion on each side of their chest. On the day of immunisation 
and 48 h later, mice were injected i.p. with 200 ng of pertussis toxin (ListBiological 
Laboratories, Campbell, CA, USA) diluted in sterile PBS. Mice were scored daily 
for clinical signs of EAE using the following scale: 0, no clinical disease; 1, loss of 
tail tone; 2, unsteady gait; 3, hind limb paralysis; 4, forelimb paralysis; 5, death. 
Scoring was performed by the same individual throughout the experiment to 
ensure consistency. 
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2.5. Cells tracking from the skin to the LNs  
 
In order to follow cells migrating from the skin to lymph nodes, two different 
methods were used: FITC-painting and NP injection. Mice were shaved 1 day 
before treatments. FITC powder (Sigma-Aldrich, Saint Louis, MO, USA) was 
dissolved in a 50 : 50 (v/v) mixture of acetone and dibutylphthalate to obtain a 1% 
FITC solution and 20 μl were applied onto the back skin of mice (74). For NP 
injections, 5×108 1µM unmodified red fluospheres (Invitrogen, Life Technologies, 
Darmstadt, Germany) were injected s.c. (75). 12 h later, mice were UV irradiated 
on their back (5 kJ/m2) and then sacrificed after 24h. Skin and antigen-draining 
inguinal lymph nodes were harvested and fixed in 4% paraformaldehyde to 
procede with histology staining. Lymph nodes were embedded in 1% agarose gel 
and 35 µm slices were obtained using Vibratome machine (Leica Biosystem, 
Nußloch, Germany), while skins were embedded in Tissue Tek O.C.T. compound 
(Sakura Finetek, Germany) and sliced in 10 µm slices with Cryotome machine 
(Leica Biosystem, CM1950). Histology staining was performed using DAPI, 
Armenian hamster anti mouse-CD11c primary antibody (Abcam Antibodies, 
Cambridge, UK) and respectively Goat anti Armenian Hamster TRICT- or FITC- 
conjugated secondary Antibody (Jackson ImmunoResearch Laboratories, Inc., 
West Grove, PA, USA). Images acquisition was performed using a Confocal 
Microscope (Leica Biosystem,TCS SP5 II) and Macro programme was generated 
by Damir Krunic in order to quantify the NP in the LNs. 
 
2.6. Staining procedure for Flow cytometry (FACS) analysis 
 
Mice were sacrificed through cervical dislocation and skin from their back was 
removed. Epidermal and dermal layers were separated, minced and prepared as 
described elsewhere (76). In some cases, skin was removed from the mice and 
directly frozen in liquid nitrogen. Inguinal Lymph nodes were extracted, meshed 
through a 70 µm strainer to singularize them, using a plunger of a syringe to push 
them through the meshes and washed with PBS. Cells obtained from both 
procedures were then counted and seeded into U-bottom 96-well plate (1x106 
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cells/well) to proceed with staining protocols. After centrifugation, supernatant was 
removed and 200 µl of staining buffer were added to wash the plate. Further 
centrifugation was performed before resuspending the cells in 100 µl ml of staining 
buffer containing 1 µl of anti-mouse CD16/32 antibody, necessary to block Fc-
receptors. An appropriate amount of surface staining antibodies was added in 
each well, followed by an incubation time of 30 min on ice in the dark. Washing 
steps with 200 µl ml of staining buffer and centrifugations (1600 rpm, 5 min at 4°C) 
were performed before proceeding with fixation/permeabilization. This last step 
can be slightly different if it is necessary to proceed immediately with intracellular 
staining procedure or if samples have to be conserved for longer time. In the first 
case, cells are resuspended in 200 µl BD Cytofix/Cytoperm solution (Becton, 
Dickinson and Company, Franklin Lakes, NJ, USA) and incubated 20 min on ice in 
dark, then washed 2 times with (1X) BD Perm/Wash Buffer and spun down at 
1600 rpm for 5-7 min at 4°C. Cells are then resuspended in 50 µl of (1X) BD 
Perm/Wash Buffer containing appropriate conjugated intracellular antibodies and 
incubated at least 30 min on ice in dark, washed again 2 times with (1X) BD 
Perm/Wash Buffer and finally resuspended in 200 µl of staining buffer, wrapped in 
aluminium foil and kept at 4°C until acquisition. For long-term preservation, cells 
are fixed by resuspending in 200 µl of 4% formaldehyde for 20 min. on ice in the 
dark, then washed 2 times with Staining buffer and kept on ice in the dark for the 
next 24 h or frozen at -80˚C in 90% FBS and 10% DMSO. The antibodies used for 
these studies were purchased by eBioscience (San Diego, CA, USA). To analyze 
different immune populations, several antibodies were used (Table 2).  
UV-Tregs 
CD4-
PacificBlue 
CD25-FITC 
FoxP3-
APC 
CD62L-
PercPy5.5 
 
T-regs 
CD4-
PacificBlue 
CD25-FITC 
FoxP3-
APC 
  
Langerhans 
CD11c – 
PECy7 
CD45 – 
PacificOrange 
MHCII – 
PacificBlue 
CD40- 
APC 
EpCam- 
FITC 
Dendritic 
cells 
CD45- 
PacificOrange 
CD11c- PE    
Table 2. Antibody panel used for staining immune cells of interest in skin and lymph nodes of mice. 
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Data were collected with a BD FACS Canto II Flow Cytometer (Becton, Dickinson 
and Company, Franklin Lakes, NJ, USA) and analyzed with FlowJo software 
(Treestar – Data Analysis Software). For skin samples, cells were sorted using a 
BD FACS-Aria II Cell Sorter (FACS Core Facility – DKFZ) and collected in 350 µl 
RLT-buffer/ beta-Mercaptoethanol (1:100 ß-Me in RLT buffer, Qiagen Hilden, 
Germany) for further RNA extraction. 
 
2.7. Proliferation assay and Enzyme Linked Immunosorbent Assay (ELISA) 
 
Mice were sacrificed through cervical dislocation 8 days after immunisation. 
Inguinal Lymph nodes and spleens were collected and meshed through a 70 µm 
strainer, ACK lysing buffer was added to remove blood cells and, after washing 
steps using PBS, cells were counted. 5x105 cells / well were seeded in a 96 well 
plates U-bottom and stimulated for 48, 72 or 96h with different MOG 
concentrations or other stimuli like PLP and ConA as respectively negative and 
positive controls. After this time, proliferation plates were pulsed with 50 µCi (50 µl 
RPMI + 3H-Thymidin) and frozen 20 h later. 3H-Thymidin incorporation was 
measured with a MicroBeta TriLux (Perkin Elmer, Waltham, MA, USA). Elisa 
plates were harvested after 72 and 96 h, supernatant was transferred to 96 well 
plates F-bottom and frozen. Elisa assays were performed following ELISA Ready-
SET-Go Kit protocols for murine IL-2, IL-6, IL-10, IL-12, IFN-g and TNF-a 
(eBioscience, SanDiego, CA, USA).  
 
2.8. Tissue specimens and immunohistochemistry 
 
At day 15 post immunisation, EAE mice were sacrificed through intracardial 
perfusion with PBS, spinal cords were collected and preserved in 4% 
paraformaldehyde for 24h and then transferred in 30% sucrose solution and kept 
at 4°C. Samples were then cut into pieces and embedded in paraffin using Leica 
EG1160 (Paraffin Embedding). Slices were obtained using Microm HM 355S 
(Microtome for Paraffin Slices) and let dry ON. Stainings for CD3 and MAC3 were 
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performed with the following protocol as standard procedure to identify immune 
cell invasion (CD3) or activated macrophages / microglia cells (MAC3): paraffin 
was removed from the slices through subsequent EtOH dilutions, then 0.2% citrate 
buffer pH=6 was used as antigen retrivial and endogenous Peroxidase was 
quenched. First Ab was applied and left incubating ON at 4°C. Next day secondary 
Ab was applied for 1h at RT, then ABC kit was used to stain slides for 1h. DAB 
staining and Hämalaun counterstaining were performed before repeating the 
dehidratation procedure with EtOH scale and then sliced were mounted using 
Eukit (Fluka, Sigma.Aldrich). Images acquisition was performed using a Cell 
Observer Microscope (Olympus FluoView FV1000) and Macro programme was 
generated by Damir Krunic in order to quantify positive cells. At day 10 post 
immunisation, teriflunomide and control mice were sacrificed, organs were 
preserved in Roti®-Histofix 4.5% (Carl Roth, Karlsruhe, Germany) and 
hematoxylin and eosin staining (H&E) was performed in collaboration with Prof. H-
J. Gröne, Cellular and Molecular Pathology Dept., DKFZ. 
 
2.9. Magnetic-activated cell sorting 
 
LN cells were also sorted using CD4+ T Cell Isolation Kit and Magnetic 
Technology (MACS - Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were 
resuspended in 500µl of sterile FACS buffer (PBS + 3% FBS + 2 mM EDTA), 
stained with 5 µl of anti-mouse CD16/32 and incubate for 15min on ice to block Fc-
receptors; then 5 µl of biotinylated anti-mouse CD4 were added and incubated on 
ice for 30 min. After proper washing steps using sterile FACS buffer, cells were 
resuspended in 180 µl FACS buffer with the addition of 20 µl of anti-biotin 
Microbeads (Miltenyi Biotec, Germany) and incubated on ice for 20 min. Finally 
cells were washed with sterile FACS buffer and prepared for manual cell 
separation procedure. Considering the number of cells to sort, MS or LS-columns 
can be used. In principle, Miltenyi Biotec protocol was followed: columns were 
prewet with FACS buffer, cell suspension was applied onto the column through a 
cell strainer, column was then washed repeatedly with FACS buffer and samples 
were collected. Sorted cells were then resuspended in 350 µl RLT-buffer/ beta-
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Mercaptoethanol (1:100 ß-Me in RLT buffer, Qiagen, Hilden, Germany) and used 
directly for RNA extraction or frozen at -80°C. 
 
2.10. RNA extraction and quantitative PCR analysis 
 
Organs from teriflunomide treated mice were snap-frozen in liquid nitrogen and 
then pulverized using a Mixer ball mill MM400 with a frequency of 28Hz, for 30 
seconds (Retsch GmbH, Haan, Germany). Beakers were previously cooled with 
liquid nitrogen, so that the samples remained frozen during the procedure. RNA 
was then extracted using peqGOLD Total RNA Kit (PeqLAB Biotechnologie 
GmbH, Erlangen, Germany). RNA was also isolated from cells collected in RLT 
Buffer, using RNeasy Mini-Kit (Qiagen, Hilden, Germany). Briefly, one volume of 
70% ethanol was added to each lysate and mixed well by pipetting, then up to 700 
μl of each sample was transferred to an RNeasy Mini spin column placed in a 2 ml 
collection tube and centrifuged for 15 seconds at ≥8000 x g. Flow-through was 
discarded and same procedure was repeated after adding respectively 700 μl of 
buffer RW1 and 500 μl of buffer RPE adjusted with ethanol. Buffer RPE was 
added a second time, but centrifugation time was then extended to 2 minutes and 
another minute was necessary to dry the membrane. Finally each RNeasy spin 
column was placed in a new 1.5 ml collection tube, 30–50 μl RNase-free water 
were directly added to the spin column membrane and centrifugation step 
occurred once more for 1 min at ≥8000 x g to elute the RNA. For both procedures, 
RNA yield was finally measured with a NanoDrop 1000 (ThermoScientific, 
Darmstadt, Germany), a quantity equal to 10 μg was used to obtain cDNA, 
following the protocol shown in Table 1. High Capacity CDNA Reverse 
Transcription Kit (Applied Biosystem - Foster City, CA, USA) was used. Finally 
cDNA was preserved at -20°C or directly used for quantitative analyses. QRT-
PCRs were performed in an ABI 7000 thermal cycler with SYBR Green PCR 
Mastermix (Applied Biosystems) and specific primer mixes. All the primers were 
designed based on the cDNA sequence of each target and housekeeping gene, 
spanning at least one intron to eliminate or distinguish amplified contaminating 
fragments from genomic DNA. PCR reactions were checked by including no-RT-
controls, by omission of templates and by both melting curve and gel analysis. The 
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size of the amplicons was analyzed by loading the samples and a 100 bp ladder 
(Life Technologies) on a 2% agarose gel, which was then stained with ethidium 
bromide and analyzed under UV light. Standard curves were generated for each 
gene. Relative quantification of gene expression was determined by comparison of 
threshold values. All samples were analyzed in duplicate in two different dilutions. 
All results were normalized to GAPDH (77, 78). 
Primer sequences were (5’-3’ forward, reverse): 
GCCTTCCGTGTTCCTACCC, CAGTGGGCCCTCAGATGC (Gapdh), 
GCCCTTCCCGCAAGATGTTAT, CAGGGGTGGACTTTAATGCAA (Ahr), 
CTACAGGACATTTGAGAAGGGC,AGGTCCAAAACAATCGTGATGAC (Cyp1a1), 
TTGGAAATTCTTCTGTAGAGACCA,CTTCTTCAATTAGTCGAACAACAGA 
(Tiparp). 
 
 
Table 3. Protocol followed for the conversion of RNA in cDNA using High Capacity CDNA Reverse 
Transcription Kit.  
 
2.11. Microarray – Genomics Core facility, University of Heidelberg 
  
RNA samples obtained from lymph nodes of irradiated and control mice were also 
used for a microarray test. Briefly, RNA was kindly checked for quality controls by 
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the Core Facility Microarray Unit of DKFZ, using RNA Eukaryote Total RNA Pico 
kit. Upon samples acceptance, a MouseWG-6 v2.0 Expression BeadChips 
(Illumina, San Diego, CA, USA) was used. Samples were labelled and hybridized 
to the microarray, all the steps were monitored and image acquisition, single chip 
analysis as well as normalization across all of the samples was performed. In 
depth analyses were performed using Ingenuity software (Qiagen, Hilden, 
Germany) and GSEA software (Gene Set Enrichment Analysis – Broad Institute, 
USA). Statistical analysis of the data were performed in collaboration with Alex 
Brenner and Thomas Hielscher from the Biostatistics Dept. of DKFZ. 
 
2.12. Cloning strategy 
 
With the aim of having a new AhR reporter mouse, different cloning strategies 
were developed. The protocol followed required as first step the design of specific 
primers, in order to insert the fragment of interest in a backbone plasmid. That was 
done using Geneious software and online tools offered by Sigma Aldrich. Primers 
were then used for a PCR amplification step, using the Phusion® HF Buffer Pack 
kit (New England BioLabs Inc., Ipswich, MA, USA ). Successful amplicons were 
checked on band size, loading the PCR products and running a 1% agarose 
electrophoresis gel. GenEluate PCR Purification kit (Sigma Aldrich) was then used 
to purify the right amplicons, that still needed to be cut with specific restriction 
enzymes. This last step was usually performed in parallel with the backbone cut, 
since both reactions ran at 37°C for 1, 5 h. After further purifications, proportional 
amount of insert and vector were calculated for the ligation step, mediated by the 
T4 ligase. Products were further used to transform competent bacteria (E.Coli 
DH5α), which were then distributed on petri dishes previously prepared with 
appropriate antibiotic. The next day, grown colonies were picked and further 
expanded before proceeding with MINI-preparation using QIAspin mini prep Kit 
(Qiagen, Hilden, Germany). Products were digested, checked on gel and sent to 
GATC Biotech for sequencing. Results were compared with the predicted ones, 
using Geneious software and only the correct ones were further amplified, using 
NucleoBond xtraMaxi kit (MACHEREY-NAGEL GmbH & Co. KG, Düren, 
Germany). The products obtained were used for in vitro tests: cells were trasfected 
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with the plasmid of interest, treated with known compounds activating the AhR (i.e. 
TCDD) and fluorescent signal was acquired on confocal microscope. 
 
2.13. DRE_Luc mice and Total Body Imaging 
 
DRE_Luc mice are reporter mice generated in our laboratory as an important tool 
to monitor the AhR activation in vivo. In order to perform total body imaging, 
DRE_Luc mice were shaved on the back with electric clippers 1 day before 
starting the treatment. Mice were then irradiated at different time point and AhR 
activation was checked using IVIS® Lumina Imaging System. Briefly, mice were 
injected i.p. with 150µl StayBriteTM D-Luciferin (Enzo Life Science) diluted in PBS 
(30mg/ml), narcotized with Isofluorane flowing through a XGI-8 Gas Anesthesia 
System and imaged for 10min using IVIS machine. Data were collected and 
analyzed with Living Image software (PerkinElmer, Waltham, MA, USA). 
 
2.14. High-performance liquid chromatography (HPLC) measurements 
 
High-performance liquid chromatography was performed in collaboration with Ece 
Gaffarogullari at the Institute of Pharmacy and Molecular Biotechnology, 
Department of Chemistry (University of Heidelberg) in order to measure 
Teriflunomide and with Gernot Poschet from the Metabolomics Core Technology 
Platform, (University of Heidelberg) for the Trp and its metabolites derived from UV 
irradiation. Both procedures are hereby described. 
Teriflunomide measurements 
Standard controls and samples were prepared as shown elsewhere (79). Briefly 
teriflunomide was dissolved in Phosphate buffer (pH 8, 0,05 M) and used for 
serially dilutions, blank plasma was spiked to obtain different teriflunomide 
concentrated samples and fresh plasma was obtained to every treated mouse. 
100µl of each sample was add to 200µl of acetonitrile and prepared for HPLC 
measurements. All HPLC measurements were performed. 50 µl of the samples 
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were injected to 5u C18 300A column (5 µm, 250 x 4.6 mm) (Phenomenex , 
Aschaffenburg, Germany) connected to a Agilent Series 1100 HPLC machine 
(isocratic 75% buffer A/B, 25 °C, 1 ml/min) with a diode array detector 
(Absorbance: 260 nm and 305 nm, slit width: 4 nm). Buffer A: 0.05 M sodium 
acetate pH 2.5 (adjusted by glacial acetic acid), Buffer B: acetonitrile. 
Teriflunomide was detected after 9.5 min. The data was analysed by Agilent 
ChemStation (Agilent Technologies, Santa Clara, CA, USA), and the calibration 
curve for the standard samples was generated.  
Determination of tryptophan, FICZ and untargeted metabolomics 
Tryptophan was extracted from homogenized skin samples with 0.5 ml of 2.4% 
perchloric acid in an ultrasonic ice-bath for 10 min. To prevent hydrolysis of Trp 
the pH was neutralized by addition of 17µl 10 M NaOH afterwards. To extract 
apolar metabolites (e.g. FICZ), the second aliquot was extracted with 0.5 ml of 
acetonitrile (ACN) first, as described above. After centrifugation for 5 min at 4°C at 
16.400 g the pellet was reextracted with 0.5 ml methanol and centrifuged. Both 
supernatants were combined. Prior analysis, homogenates were centrifuged again 
for 10 min at 4°C to remove remaining cell debris. Compounds were separated by 
reversed phase chromatography on an Acquity HSS T3 column (100 mm x 2.1 
mm, 1.7 µm) connected to an Acquity H-class UPLC system (Waters GmbH, 
Eschborn, Germany). For the determination of Trp, the column was heated to 
42°C and equilibrated with 5 column volumes of 97% buffer A (0.1% formic acid) 
and 3% buffer B (0.1% formic acid in ACN) at a flow rate of 0.55 ml min-1. Clear 
separation of Trp from interfering compounds was achieved by increasing the 
concentration of buffer B in buffer A as follows: 1 min 3% B, 4 min 23% B, 4.1 min 
85% B, 6 min 85% B, and return to 3% B in 2 min. To determine FICZ, the column 
was equilibrated with 5 column volumes of 60% buffer A and 40% buffer B and the 
following gradient was used: 0.5 min 40% B, 5.5 min 95% B, 7 min 95% B and 
return to 40% B in 2 min. Trp and FICZ were detected by fluorescence using an 
Acquity FLR detector (Waters). The FLR detector was set to different parameters 
for Trp and FICZ: excitation: 254 nm, emission: 401 nm, gain: 100 for the first and 
excitation: 525 nm, emission: 390 nm, gain: 1000 for the second. For 
quantification, ultrapure standards were used (Trp from Sigma-Aldrich, FICZ from 
Enzo Life Scientific). Data acquisition and processing was performed with the 
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Empower3 software suite (Waters). In order to perform untargeted metabolomics, 
metabolites were extracted from 30 mg homogenized skin samples with 0.5 ml of 
ACN, as previously described. 5 µl of each sample were injected onto a reverse-
phase Acquity HSS T3 C18 column (Waters), using a binary Acquity UPLC system 
running a gradient (composition of mobile phases A and B as described above).  
Each sample was resolved for 10 min at a flow rate of 0.5 ml min−1. The gradient 
consisted of 97% A for 0.5 min, a ramp to 77% A from 0.5 min to 4.0 min, another 
ramp to 95% B from 4.0 to 12.0 min, a hold at 95% B until 12.5 min, then returned 
to 97% A from 12.5 min to 12.6 min, and hold at 97% A until 15 min. Column 
temperature was maintained at 40°C throughout the run and samples temperature 
was constantly kept at 8°C. The column eluent was introduced directly into the 
mass spectrometer by electrospray ionization (ESI).  
Mass spectrometric analysis was performed on a Xevo qTOF G1 (Waters) 
operating in both positive and negative mode. The capillary voltage was set to 0.8 
kV and 3 kV, and the cone voltage of 30 V and 25 V, respectively. The desolvation 
gas flow was set to 950 l h−1 and the temperature was set to 550°C. The cone 
gas flow was 30 l h−1, and the source temperature was 120°C. Accurate mass 
was maintained by introduction of Lock-Spray interface of Leucine-enkephalin 
(556.2771 [M+H]+ or 554.2615 [M−H]−) at a concentration of 4 ng µl−1  in 50% 
ACN and a rate of 8 µl min−1 (scan time 0.5 sec, interval 20 sec, scans to average 
3). Mass signals were acquired in centroid mode from 50 to 1000 mass-to-charge 
ratio (m/z) in MS scanning using the MassLynx 4.1 software package (Waters). 
Data analysis of raw mass spectrometric data was carried out using the 
MarkerLynx add-on tool (Waters). 
 
2.15. Statistical Analysis 
 
Data are expressed as mean  s.e.m or as boxplots designed using Sigma Plot. 
Analysis of significance was performed using the Student’s t-test or Mann-Whitney 
Rank Sum Test (SigmaPlot). P values < 0.05 were considered significant. 
Correlations were analysed by Spearman rank correlation (Sigmaplot).  
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3. Results 
 
3.1 Project 1: Benefits in multiple sclerosis treatment via UV irradiation 
 
3.1.1. UV irradiation delays onset of EAE in wt mice, but not in AhR-/- mice  
 
Becklund et al. (27) suggested that EAE can be suppressed by UV irradiation in a 
vitamin D3 independent manner. Our hypothesis is that not vitamin D3, but 
tryptophan mediates the immune response via the involvement of the AhR. 
Therefore we first asked whether the clinical course of EAE would have changed 
in the absence of the AhR. To address this question, WT and AhR deficient mice 
(AhR-/-) were subdivided into two groups. One group received a UV pre-treatment 
with a 2.5 KJ/m2 dose administration every second day, starting from one week 
before immunisation, while the other group received a sham irradiation treatment. 
Irradiated as well as control mice were immunised with MOG35–55 peptide and 
pTox, while the irradiation procedure continued every second day during the 
experiment time. The clinical EAE course of WT and AhR-/- mice was observed 
during the whole experiment. At day 15 post immunisation, 6 mice from wt groups 
were sacrificed and spinal cords were isolated in order to prove, via histological 
staining, a corresponding different T-cell invasiveness status. Experimental 
procedure and results are depicted in Figure 3.1. 
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Figure 3.1. In vivo UV irradiation. A. Schema of the experimental procedure applied: mice were 
irradiated /sham treated every second day during the whole experiment. At day zero (d0) and day 2 
(d2), mice were immunised in order to induce EAE. B. Scoring curve during the disease 
development for WT and AhR-/- mice. C. and D. Immune cell invasion, visualized by CD3 
histological staining and quantification in spinal cords of wt mice, n = 6, * p <0,05. 
 
3.1.2. AhR is activated by UV irradiation in a time and dose dependent manner 
 
To support the hypothesis of an AhR involvement, we used DRE_Luc mice, 
reporter mice created in our laboratory and used as tool to monitor AhR activation 
in vivo. Once DREs are induced, it is possible to quantify and localize specific 
luminescence in the mice, which corresponds to the AhR activation. For the 
measurement, mice were shaven on their back, irradiated and AhR activation was 
measured using an IVIS system. The experiment was performed with different UV 
doses and the signal was measured 24h later. As seen in Fig. 3.2., the AhR 
activation is proportional to the UV dose the mice received and the signal is 
specifically located on the irradiated region. Luminescence is lost, once the skin 
layer is removed. Further, a time course experiment was performed with a dose of 
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5 kJ /m2. Surprisingly, the signal was clearly detected as early as three hours after 
the irradiation.  
 
Figure 3.2. Dose and time course of DRE_Luc reporter mice. A. Luciferase intensity was measured 
24h after irradiating mice with different UV doses. B. Quantification of the luciferase intensity in the 
ROI (red circle). C. A single dose of 5 kJ /m
2
 was used for irradiating mice and the signal intensity 
was measured at different time point. For further experiments, measurements were done after 4h 
with a 5 kJ /m
2
 single dose. 
 
3.1.3. Cyp1A1 is up-regulated in the skin cells from irradiated mice 
 
We next investigated how the skin immune compartment is modulated during UV 
irradiation. The skin is constituted by two layers, epidermis and dermis, where 
keratinocytes and immune cells are found (Fig. 1.5). In collaboration with the 
group of Prof. Schäkel (Skin Clinic Heidelberg), dermis and epidermis layers were 
separated, immune cells were isolated and stained to perform FACS-sorting. Data 
showed that, in the epidermis, the Langerhans cell (LC) population expressed 
higher levels of MHC II after UV irradiation. Vice versa, we observed a diminishing 
number of MHC II positive cells in the dermis layers of irradiated mice and this 
48 
 
decrease was more abundant in WT mice (Fig. 3.3A). These cells were 
subsequently utilized for RNA extraction in order to quantify gene expression. 
Cyp1A1 primers were used to perform quantitative PCR analyses. Results showed 
an increase of Cyp1A1 mRNA levels in irradiated cells, supporting an involvement 
of the AhR in the UV response (Fig. 3.3B). 
 
Figure 3.3. Skin analysis. A. Representation of flow cytometry analyses of epidermis and dermis 
samples from WT and AhR-/- mice (n=6 per group). Cells plotted are CD4+, CD25+, Epcam+ and 
MHCII+, markers used to stain LCs. In epidermis, UV irradiated samples showed a shift to higher 
MHCII+ levels. In dermis, cell subpopulations responded to irradiation treatment with higher 
variance than control groups. B. Cyp1A1 mRNA expression levels in the sorted cells are shown. 
 
3.1.4. Determination of AhR activators 
 
Once the involvement of the AhR and its UV irradiation specific activation were 
proved, the following step was to determine factors produced by UV irradiation that 
activate AhR in this specific manner. From the studies published by Rannug et. al. 
(80), we postulated that tryptophan and in particular its photoproduct FICZ might 
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be involved. In vitro studies were performed in collaboration with the Metabolomic 
Platform present in the Heidelberg University Campus, in order to optimize the 
FICZ detection conditions via HPLC. As described by Wincent et al. (69), a 80 µM 
Trp solution was prepared in dH2O and irradiated for different time and different 
doses. We managed to detect a small amount of FICZ starting from a UV dose of 
5,3 kJ /m2, corresponding to 30 min irradiation time at 40 cm distance from the 
lamps. The chromatogram also showed that there were further compounds 
produced by UV irradiation, similar to FICZ and potentially comprise more 
hydrophobic FICZ metabolites like ICZ (Fig. 3.4A). Subsequently, in vivo 
experiments were performed using DRE_Luc mice, that were irradiated with a UV 
dose of 5 kJ /m2 and sacrificed 24 h later. Furthermore, WT and AhR-/- mice were 
subjected to a long-term UV experiment, where they received a dose of 2.5 kJ /m2 
every second day and then sacrificed at day 8 p.i. Skin from these mice was 
collected, frozen and prepared for HPLC measurements. Since FICZ is a potent 
AhR activator, pure FICZ (Enzo Life Science) was used as standard reference in a 
range of 20- 500 nM, to mimic the natural amount, but no FICZ was detectable in 
the skin biopsies of the animals (Fig. 3.4B). Interestingly, there was a significant 
increase of Trp levels in the skin of long-term irradiated mice (Fig. 3.4C).  
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Figure 3.4. UV metabolites. A. Schematic representation of the hypothesis proposed by Rannug et 
al. B. In vitro studies to detect FICZ, water solution was irradiated for different times, HPLC 
measurements were performed, however no FICZ was detectable with less than 30 min of 
irradiation. Even after 12 h, the amount detected was still very low. C and D. Mice were irradiated 
for one single time or for several times (as described in 2.3). FICZ was not detectable in the skin 
under either condition, however Trp levels increased after irradiation. n = 6, * p <0,05. 
 
 
Nevertheless, untargeted mass spectrometry was performed, looking for other 
candidates responsible for the AhR activation. From the skins of DRE_Luc mice, 
two compounds drew our attention: inosine and sulfolane (Fig. 3.5).  
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Figure 3.5. Untargeted mass spectrometry comparing mouse skins with and without UV treatment. 
Mass spectrometric analysis was performed on a Xevo qTOF G1 mass spectrometer operating in 
both positive and negative mode. Data analysis of raw mass spectrometric data was carried out 
using the MarkerLynx add-on tool (Waters).  
 
Based on the signals extracted for the corresponding masses, their chemical 
structure and some hints from literature (80) further tests were performed. HepG2 
cells stably transfected with a reporter plasmid expressing luciferase under the 
control of 3xDRE were treated with 5mM Sulfolane (Sigma Aldrich), 5mM Inosine 
(Sigma Aldrich), or DMSO and TCDD as negative and positive controls, 
respectively. After 24 h, the medium was removed and luciferase substrate was 
added. After 5 min incubation in the dark, cells were imaged using an IVIS 
machine and pictures were acquired at different exposure times (Fig. 3.6A). 
Exposure to inosine resulted in activating AhR and further investigation were 
performed in vivo, using the DRE_Luc reporter mice. Inosine was dissolved in 
PBS (4 µM) and injected s.c. at the back of the mice. After topical administration a 
luciferase signal was detected after one hour and it stayed stable for the next six 
hours, indicating that inosine is capable of activating the AhR in the skin (Fig. 
3.6B). 
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Figure 3.6. Untargeted mass spectrometry validation. A. HepG2 cells carring 3xDRE construct 
were treated with H2O (1), Inosine (2), Sulfolane (3), DMSO (4) or TCDD (5) and luciferase assay 
was performed 24 h after treatment using IVIS luminometer. Quantification analysis was performed 
using ImageJ, where well 6 was used for background subtraction and all the data were further 
normalised to the water sample. B. In vivo tests were performed using DRE_Luc mice. The first 
mouse received sham injection only with PBS while the others were injected s.c. with 200 µl of 
inosine 4 µM (red circle), are respectively imaged after 1h (@), 2h (+) and 6h (#). n=3 mice per 
group. 
 
3.1.5. UV irradiation does not influence the cell trafficking to the lymph nodes 
 
We then focused on the cells that are able to migrate and diffuse in the body to 
induce an immune response. This characteristic belongs especially to DCs and 
LCs. They are able to take up antigens from the skin and process them, becoming 
fully functional antigen-presenting cells (APCs). APCs then traffic to secondary 
lymphoid tissue and there they switch their functions, losing the ability to migrate, 
but gaining the capacity to interact with naive T-cells. We asked whether UV 
irradiation interferes with any of these steps. In order to address this question, 
experiments to follow cell trafficking were performed. A FITC solution was painted 
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on the back of the mice, which were UV or sham irradiated 12 h later and then 
sacrificed after another 24 h. Skins and LNs were preserved and analysed as 
described in 2.5. However, only unspecific FITC signal could be detected, because 
the fluorescent solution arrived to LNs mainly via lymph flow. Therefore, instead of 
FITC, red fluorospheres were injected s.c and tracked in a time course 
experiment. Red particles were detectable in LN sections from 36h post injection 
and co-staining with FITC-CD11c Ab confirmed that part of the fluorospheres 
injected have been taken up by DCs and LCs in the skin before arriving to LNs 
(Fig. 3.6). With the kind help of Damir Krunic from the Microscope Core Facility in 
DKFZ, a Macro was created in order to automatically count and quantify the 
amount of fluorospheres detected in LNs sections from UV irradiated or control 
mice. The experiments did not show a difference in the number of nanoparticle 
(NP) detected, suggesting that UV irradiation does not affect the migration of 
phagocytic cells from the skin to the secondary lymphoid organs. 
 
Figure 3.7. NP trafficking. Immunohistochemic pictures of skin and LN sections 36 h post red 
fluorosphere (NP) s.c. injecteion. DAPI is stained in blue, CD11c+ cells were stained with FITC 
(green). The yellow arrow indicates a CD11c+ cell, while the red arrows showed CD11c+ cells that 
took NP up, indicating that not all the Cd11c+ cells took NP up. On the right, representative 
pictures of LNs sections from irradiated and control mice, where NP are in yellow. A macro was 
created in order to count the NP and results are depicted in the graph. There is no significant 
difference between the two groups. 
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3.1.6. UV-Tregs 
 
DCs and LCs travel through lymphatic vessels and, via chemotaxis, arrive to LNs, 
where they meet the T cells. This crucial process, called priming, requires an 
exchange of information between APCs and naïve T cells, it is mediated by 
specific molecules on the APC membrane called major histocompatibility complex 
(MHC), by which the T cell fate is decided. CD4+ T cells recognize the antigen-
class II MHC molecule complex on the membrane of the APCs, while CD8+ T cells 
recognize MHC class I. The next step for our studies was therefore the analysis of 
the LN compartment, where DCs from the skin meet and prime the T-cells. 
Schwarz et al. proposed that LCs, damaged by the UV irradiation, can still migrate 
to LNs and prime a special kind or regulatory T-cells, called UV-Tregs (82, 83). 
These cells, generated upon UV irradiation, express the lymph node homing 
ligand CD62, besides the classical markers for T-regs like CD4, CD25 and FoxP3. 
As many other T-regs, they can inhibit immune reactions and may also harbour 
therapeutic potentials, as proved for contact hypersensitivity (CHS). Experiments 
to detect them also in our EAE context were performed. Mice were sacrificed at 
day 8 p.i., a LN single cell suspension was prepared and stained for FACS 
measurement. Stainings were performed using Abs described in Table 3. and 
results are shown in Fig. 3.8. Interestingly, we were able to identify UV-Tregs in our 
setting and further studies demonstrated that these cells are not present if the 
mice are irradiated with higher doses but for shorter time (data not shown).  
 
Figure 3.8. Density plots representative of an experiment to detect UV-Tregs. Cells were stained with 
CD4-PB, CD25-FITC, FoxP3-APC and CD62L-PerCpCy5.5 Abs. The population of interest is 
marked with a red circle. FACS analyses were performed using FlowJo, n = 6 mice per group, *** 
for p-value < 0,001. 
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Once identified, we wanted to analyse their function and understand whether they 
were responsible for the differential EAE onset observed in our initial studies. 
Therefore, proliferation assay and ELISA assay were performed, using the same 
experimental procedure described before. Briefly, mice from irradiated and non-
irradiated groups were sacrificed 8 days p.i., inguinal draining LNs and spleens 
were collected to prepare single cell suspensions and counted. Cells were seeded 
and stimulated in triplicates for each conditions: untreated, stimulated with 1 µg/ml 
MOG, 5 µg/ml MOG, 10 µg/ml MOG, 20 µg/ml MOG or internal controls (PLP and 
ConA). In vitro stimulation was required to detect cells, which recognise 
specifically the peptide MOG and, after activation, can proliferate or release 
cytokines. Results are shown in Fig. 3.9. 
 
 
Figure 3.9. Immuno-assays in LNs. A. Analyses of proliferation assay from lymphocytes at 48 and 
72 h after MOG stimulation. B. Analyses of proliferation assay from spleenocytes at 48 and 72 h 
after MOG stimulation. Cells were pooled from different mice (n = 9 mice per group). All data are 
normalised on no MOG and S.E.M is used for error bars. Red columns for UV irradiated groups, 
blue for control group. C and D. ELISA assay performed from same mice. IL-12 (C.) and TNF-a 
(D.) are the only cytokines that differed between the two groups, although not significantly. 
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3.1.7 Microarray, a tool to open a new prospective or to close the circle 
 
In order to further investigate the LN compartment and to gain a broader overview 
of the pathways potentially activated upon UV irradiation, we performed large 
scale gene expression analysis. CD4+ T cells were MACS-sorted from draining 
LNs of irradiated and control mice, respectively, RNA was extracted, quality-
checked and subjected to a MouseWG-6 v2.0 Expression BeadChips (Illumina). 
Two approaches were followed for the data analyses. First, all genes were plotted 
in a volcano plot, visualizing their fold change and the significance of this change 
(p-value). The 200 most significantly regulated genes were chosen and, using IPA 
and GSEA, the best 60 were further analysed. Pathway analysis indicated that 
most of these genes were involved in B cell development or in antigen response 
(Figure 3.10). 
 
 
Figure 3.10. Microarray data. A. Volcano plot depicting the distribution of all measured genes, 
where up-regulated genes have a fold change > 1 and down-regulated < 1. Furthermore, the 
significance of the regulation (p-value) was considered as important parameter to set a cut-off 
57 
 
(above the red line) to chose candidates to proceed with in further analyses. B. Pathway analysis 
using Ingenuity Pathway Analysis (IPA) software from Qiagen. The most statistically significant 
canonical pathways are listed, blue bar height is proportional to the number of genes from the 
dataset matching the pathway, the orange line indicates the threshold of p value < 0.05 as 
calculated by Fischer's test. c) Pathway Analysis using Gene Set Enrichment Analysis (GSEA) 
from Broad Institute. The 60 most significantly regulated genes from the dataset were compared 
with all the data set collections from GSEA and the best overlap was found for 9 genes (listed on 
the right side). Green bar indicates high significant FDR q-value (< 0.05). 
 
Another approach was, taking into consideration all genes listed in the raw data 
sheet, performing gene enrichment analysis. This tool is offered by the Broad 
Institute in Boston and allowed us to compare our list of genes with all the 
pathways present in different databases. This resulted in a list of 30 pathways 
strongly matching with our genes and a direct visualization of the up- and down- 
regulated genes in control and treated samples. Results are shown in Figure 3.11. 
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Figure 3.11. Pathway Analysis using GSEA. A. The node-edge diagram represents the best 30 
pathways identified using KEGG database (Kyoto Encyclopedia of Genes and Genomes). Colours 
are proportional to the adjusted p-value of the pathways, where red stands for up-regulated and 
blue for down-regulated pathways. Node size is proportional to the number of genes from our 
database matching KEGG, where the minimum is corresponding to 14 genes and the maximum to 
167. Thickness of the lines connecting the pathways is also proportional to the number of genes in 
common, with a minimum of 1 gene and a maximum of 44 genes. B and C. Gene set enrichment 
representation of the most important pathways. 
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3.2 Project 2: Teriflunomide metabolism is dependent on the aryl 
hydrocarbon receptor  
 
3.2.1 Lethal effect of TER in AhR-/- mice 
 
Following our initial hypothesis of an AhR involvement in the immunomodulatory 
response to TER as a potential AhR ligand, we immunised WT and AhR-/- mice 
with MOG35-55 peptide in order to induce EAE. Oral TER treatment (10 mg/kg/day) 
ameliorated disease scores and delayed the onset of disease in WT mice and in 
AhR-/- mice. In fact, WT mice treated with the sole methylcellulose (MC) showed 
paralysis signs from day 10 p.i., while the group treated with TER did not, reacting 
to the treatment as shown before (13). The same situation was observed in AhR-/- 
mice receiving control treatment, but further comparison with the corresponding 
TER- treated group was not possible.  In fact, TER-treated AhR-/- animals lost 
significantly more weight than WT mice, starting from day 8 after immunisation 
(day 5 after start of TER treatment) and died between day 11 and 14 after 
immunisation (day 8 – day 11 after start of TER treatment) (Fig..3.12). The dosage 
was calculated according to FDA guidelines for equivalent doses in animals (U.S. 
Department of Health and Human Services Food and Drug Administration Center 
for Drug Evaluation and Research (CDER) Estimating the Maximum Safe Starting 
Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, n.d.) and 
similar doses had been used before for the treatment of EAE in rats (12).  
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Figure 3.12. TER and EAE mice. A. EAE scoring curves of WT mice and AhR-/- mice treated 
respectively with TER or with a control treatment from 3 days p.i. Results from one representative 
experiment are shown. **p < 0.01. B. Table shows that only mice receiving control treatment were 
manifesting paralysis symptoms. nd. = not detectable, since mice in this group died. C. Mice were 
weighed daily (±SD) throughout the study to monitor disease-associated weight loss and toxicity. 
D. AhR-/- mice receiving TER treatment were affected by weight loss and morbidity, as shown in 
the Kaplan-Meier curve.  
 
3.2.2. Histology investigations   
 
All the mice were sacrificed by terminal blood collection, total blood and serum 
were then preserved for further analyses. Autopsies were also performed in order 
to check for macroscopic observations. A post-mortem external examination did 
not reveal any anomalies while, during the dissection of the animals, evident 
changes in the intestinal truck were present. Interestingly, only the AhR-/- mice 
treated with TER had darker gut compared to mice from the other groups (Fig. 
3.13A) For further investigations, intestine, liver, spleen, kidneys, stomach, lungs 
and heart of every mouse were collected and stored either in paraformaldehyde or 
shocked-frozen. Histopatology analyses performed by Prof. H.J. Gröne (Fig. 
3.13B) revealed gastritis (i) and enteritis (iii, iv) in the AhR-/- TER mice. At multiple 
sites, the villi were oedematous, the crypts demonstrated massive apoptosis and 
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necrotic epithelial cells were found (ii). As a consequence, the necrosis of the 
epithelial cells induced inflammation. In all the other organs analysed, the 
morphology was regular.  
 
 
Figure 3.13. Macro and microscopic organs analyses. A. Macroscopic analysis of the intestine of 
treated mice. AhR-/- TER mice have visibly darker intestine. B. Histologic findings in stomach and 
intestine sections from AhR TER mice. i. small ulcer of the Corpus Ventriculi (black arrows - H&E 
staining 10x). ii. apoptotic and necrotic cells at the crypt of the mucosa (red arrows - 10x). iii and iv. 
representative examples of a flat (iii) and a transmural ulcer (iv) in the small intestine (20x and 
10x). 
 
3.2.3. Blood investigations 
 
Fresh blood was preserved in coated tubes and immediately brought to the 
Analysis Centre of the Medical Clinic in Heidelberg. A complete blood cell count 
test was performed for every sample and results revealed no significant 
differences in most of the parameters considered. Interestingly, platelets were 
significantly decreasing in mice treated with TER (Fig. 3.14B) and this difference 
was even higher in AhR-/- mice. Serum was also tested in the same centre for 
GPT/ALT parameters and the values detected in AhR-/- mice treated with TER 
were 3 folds higher than the values detected in the other groups (Fig. 3.14C). 
Furthermore, HPLC measurements were performed in order to detect TER 
presence in mice serum (Fig. 3.14D). Serial dilutions from stocks of 500 µg/ml 
TER in Phosphate buffer and from blank serum spiked with 60 µg/ml TER were  
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used to generate a six point calibration standard curve, measuring samples at 260 
nm and 305 nm. The same procedure was used for the serum collected from each 
mouse. A comparison of these chromatograms with the respective controls and 
standards guaranteed that endogenous substances did not interfere with the 
assay and to avoid unspecific peaks due to serum proteins. Further analyses were 
performed, comparing peak area ratios of the samples to internal standards. 
Linearity of the curve over the concentration range 0.5–250.0 µg/ml TER was 
determined using regression analysis. These data revealed a low TER 
concentration in wt mice serum, while samples from the corresponding AhR-/- 
mice treated with TER had 2-fold higher concentrations.  
Figure 3.14. Blood tests. A. Fresh blood was collected and complete blood count was performed 
for every samples. Black bars indicate mice which received control treatment, white is for mice 
which received TER treatment. Plots show mean ± SEM; n = 3 mice per group. Results from two 
independent in vivo experiments are shown. **p < 0.01. B. Thrombocytes count was significantly 
lower in mice treated with TER. C. ALT values were measured in mice serum and results revealed 
liver toxicity in AhR-/- mice. D. HPLC analysis. Standard curves were generated using serial 
dilution of TER in Phosphate Buffer and of TER in blank serum from untreated mice. Serum from 
treated mice was collected and prepared for HPLC as described. Fig. C shows TER detection in 
four different groups. Plot shows mean ± SEM; n = 6 mice per group. Results from two 
independent in vivo experiments are shown. **p < 0.01. 
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3.2.4 TER acts via AhR 
 
As additional investigation tool, we used DRE_reporter mice. These mice allow us 
to follow specific AhR activation due to their DRE coupled Luciferase construct. 
Upon i.p. injection of Luciferase substrate, a luciferase signal is detected only if 
mice received any other stimuli that induced AhR migration into the nucleous and 
binding to the DRE sequences. Therefore, animals were orally treated every day, 
as previously described for the other mice, and images were acquired using IVIS 
system every second day. The luciferase signal was detected only in the mice that 
received TER and moreover revealed an activation of AhR localized on the front 
side (Fig.3.15B). In order to confirm an AhR activation due to TER treatment, we 
investigated whether that would cause transcriptional changes in AhR responsive 
genes. Therefore, we performed quantitative PCR analyses using cDNA obtained 
from gut, liver and kidney and GAPDH was used as housekeeping gene. AhR 
expression was monitored in all the samples, but no difference was detected 
between the treated and the control ones. On the other side, TER administration 
significantly up-regulated expression of the cytochrome p450 member Cyp1A1 in 
all the organs analysed as compared to mice receiving control treatment only. 
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Figure 3.15. TER and AhR interaction A. DRE-reporter mice carry the construct randomly 
integrated in their genome. This plasmid contains 12 times repeated DRE sequences necessary for 
the activation of the CBG99 Luciferase cassette. B. Luciferase expression in DRE-reporter mice 
after treatment. Mice were orally treated and imaged over time for bioluminescence. Signal 
intensity correlates with the colour bar on the right. The intensity of luciferase expression is shown 
on the mouse: red represents high expression, violet represents low expression. Mice were imaged 
for several days during the treatment. On the right, quantification of the luminescent signal over 
time. C,D,E. mRNA expression of AhR responsive gene Cyp1A1 from treated DRE-reporter mice 
receiving vehicle (black bars) or TER (white bars): C. liver, D. gut and E. kidney. F. No differences 
in AhR expression were detectable in the organs. n= 3 mice per group, * p< 0,05, **p < 0.01.  
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4. Discussion and final remarks 
 
4.1 Project 1: Benefits in multiple sclerosis treatment via UV irradiation 
 
MS is a very complicated neurodegenerative disease and current studies are still 
focusing on the different aspects and factors involved. Among them, the 
environmental factors as well as human habits are under investigation, especially 
from the epigenetic point of view (84, 85). We concentrated our research on one of 
these factors and analysed its immunological aspects. Therefore this thesis 
focuses on the role of UVB irradiation in activating the immune system to react 
against autoimmune cells. It is a common believe, that the sun exposure increases 
the vitamin D3 production in human bodies and this in turn can provide benefits in 
several pathologies, like diabetes, renal transplantation and even cancer (86-88). 
However, this is still a matter of debate for MS. A few years ago, Becklund et al. 
claimed that UV irradiation suppresses the disease in the murine model for MS, , 
irrespective of the involvement of vitamin D3 (27). On the same line, the 
mechanism we want to propose has been studied in murine models and proves 
that UVB irradiation is beneficial in the setting of MS. Interestingly, we were able to 
add novel aspects by seeing the involvement of the aryl hydrocarbon receptor as 
the mediator of the UV-immune response. In order to prove this, we first performed 
a classical EAE experiment, using C57Bl6 wild type mice and mice lacking the 
AhR (AhR-/-). Half of them were irradiated, half received a sham treatment and 
while there was no influence of the UV treatment in AhR deficient mice, irradiated 
wt mice showed EAE symptoms four days later compared to the corresponding 
control group. Spinal cord stainings also confirmed a higher demyelination status 
in wt mice that did not receive UV. In order to confirm the involvement of the AhR, 
DRE_Luc mice were used. These reporter mice are an important tool in our 
laboratory, they carry a specific construct, which allow us to determine the AhR 
activity. Mice irradiated with different UV doses showed AhR activation. 
Importantly, this is time dependent, proved by the fact that the signal detected in 
the back of the mice took three hours to become specific (Fig. 3.2). 
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To follow this hypothesis, we analysed the skin also from the cellular point of view. 
Epidermis and dermis from the mice were stained for FACS measurements and 
we detected an increased level of MHCII+ cells (Langerhans cells) in the 
epidermis of UV irradiated mice. In the dermis, the situation varied more, since 
there was generally a lower number of cells expressing the MHC II marker and 
some cells subsets were even lost upon UV irradiation. To further investigate the 
UV effects on the skin cells, the populations indicated by the red square in 
Fig.3.3A were isolated via FACS-sorting, RNA was extracted and quantitative PCR 
analyses were performed. As shown in the results (Fig.3.6), we detected an up-
regulation of the AhR-responsive gene Cyp1A1 in samples from irradiated mice. 
These crucial experiments strongly confirm the involvement of the AhR and its 
activation by UV and opened the way for further investigations on possible AhR 
ligands. Since a few years, our group has been investigating this receptor in the 
context of tumor growth, considering the amino acid tryptophan and its metabolites 
as important regulators (89, 90). Rannug et al. described a photoproduct of 
tryptophan generated by UV irradiation as a natural AhR ligand (69, 80). Our first 
hypothesis was then that tryptophan can be degraded by UV irradiation into 6-
Formylindolo (3,2-b) carbazole (FICZ) which could in turn via activating the AhR 
trigger the immune response in a preventive direction, delaying the onset of 
disease in mice. To prove our hypothesis,  optimization experiments were 
performed to set up the right parameters for HPLC analyses, FICZ standards were 
measurable even at low concentration, but traces of FICZ were found in irradiated 
Trp solution only after a long irradiation time. Nevertheless, HPLC analysis of the 
skin compartment was performed, however no FICZ was present with one single 
irradiation dose and not either with long-term experiments. Unexpectedly, we 
could detect higher Trp levels in skin of irradiated mice, both in wt as well as AhR-
/- mice. The increase in Trp lead us to postulate that microorganisms on the skin 
surface, upon being killed by the irradiation, release substances like Trp; which 
might explain the elevated concentration detected. Again, DRE_Luc mice were 
used to address this question, but neither images nor microbiological tests from 
their skins did help us clarifying our hypothesis. In fact, there was no difference in 
Trp levels in irradiated skin following disinfection and the only bacteria detected 
from skin swaps from control mice were Enterococcus gallinarum and Rothia sp. 
(data not shown).  
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Hence, further analyses were required to identify other AhR activators. Untargeted 
metabolomic tests were performed and two components up-regulated in irradiated 
skins were chosen for further investigation: inosine and sulfolane. We wanted to 
determine their ability to activate the AhR; for this reason in vitro as well as in vivo 
tests were performed. First, HepG2 cells, carrying a plasmid similar to the one in 
DRE_Luc mice, were treated and luciferase assays showed a strong activating 
signal for inosine, but not for sulfolane. Then, DRE_Luc mice were used for testing 
the capacity of inosine to activate the AhR in vivo. The signal detected on the site 
of injection revealed that inosine can immediately bind and activate the AhR. 
Inosine is generated by degradation of ATP and adenosine and this reaction 
seems to be impaired in MS patients, where no suppressive adenosine is 
produced (91). In 2009, Koprowski et al. also conducted a study, treating RRMS 
patients with inosine (81). Despite kidney stone formation as side effect, they 
noticed a beneficial effect on the patients. 
 
 
Figure 4.1. Schematic representation of the intra- and extra-cellular ATP/adenosine signaling 
cascades (92). 
 
ATP is also known to regulate immune cell functions via the P2X receptor (93, 94), 
to influence the cytokines production on DCs (95) and to promote TH17 
differentiation in the intestinal lumen (96). Interestingly, ATP is involved in DNA 
repair processes, where inosine is known to have antioxidant and anti-
inflammatory properties, protecting the DNA (97, 98). We can therefore speculate 
that in normal conditions, a balance between ATP and inosine is maintained, while 
in MS patients this balance is lost and less inosine is produced. With irradiation, 
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further inosine production is triggered and this has beneficial effects not only on 
the DNA repairing mechanisms, but also on the progression of MS.  
ATP is broken down to adenosine and subsequently to inosine by UVB radiation, 
which, even if in a mild dose, leads to DNA damages to be repaired. On the other 
side, higher levels of inosine can mimic the healthy conditions and, via the AhR 
activation, delay the disease onset. We then concentrated our research on the 
cellular components of the AhR-mediated immune modulation in the skin. The first 
step is the so called “trafficking”, the ability of the APCs to internalise particles and 
transport them to LNs via lymphatic vessels. Therefore we wanted to track cells on 
their way from skin to LNs, hypothesizing that UV irradiation might impair some 
cells in their ability to take up particles or in their migratory skills. As a proof, we 
used fluorescent nanoparticles, injected them s.c in the back of the mice and 
performed stainings on the skin and on the draining LNs. It was possible to detect 
the particles on the site of the injection as well as in LNs sections from 36 h after 
injection. Nevertheless, confocal microscope analyses and counting of the 
particles that reached the LNs did not reveal any differences concerning the up-
take of these particles from APCs, and neither of their migration. After the 
“trafficking”, cells reach the LNs and there “prime” T-cells. Thus, the next step was 
to analyze the LNs, looking for a different T cell profile in irradiated samples. 
Recently, Breuer et al. (99) claimed that the beneficial effect of UVB irradiation is 
mediated by tolerogenic DCs and Tregs and this is also reflected in a clinical trial 
they conducted on a small cohort of MS patients. We did not find any significant 
difference in DCs numbers, nor in CD8+ cells, but we detected a trend of 
increased Tregs, that was subsequently confirmed with a different staining panel. In 
Fig.3.8 we identify the so called UV-Tregs, a cell population significantly present 
after UV irradiation, but absent in control groups. This population is characterised 
by the expression of the classical Treg markers (CD4, CD25 and FoxP3), and 
express also CD62L, a cell adhesion molecule also known as L-selectin. Schwarz 
et al. (83, 100) identified these cells for the first time and described them to be 
specifically UV dependent. Recent literature described CD62L as a ligand to 
discriminate among the different Treg subtypes (101, 102), claiming that CD62L+ 
cells are more potent suppressors than the CD62L- population Treg cells are more 
responsive to chemokine-driven migration to secondary lymphoid organs. We also 
wanted to investigate the role of these UV-Tregs, performing proliferation assays as 
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well as ELISAs to determine cytokine expressions. As shown in Fig.3.9, cells from 
the draining LNs were barely proliferating, while in the splenocytes we were able 
to measure higher proliferation for wt cells compared to cells derived from 
irradiated mice. This correlates with the reduced proliferative response described 
by Weill et al in case of chronic UV irradiation (103). Goudy et al also described a 
limited proliferation activity associated with CD62+ cells (104), while Beissert et al. 
claim that CD62L+ Treg cells lose their migratory skills, due to their lack of other 
selectin markers (105). Furthermore, no real differences in the cytokine profile 
were measured, only IL-12 was slightly increasing in UV irradiated LNs, supporting 
the role of this cytokine in DNA repair and its ability to modulate TNFα (106-108). 
In order to further investigate the mechanism behind it, microarray analyses were 
performed, using RNA samples from draining LNs of irradiated and control mice. 
The volcano plot in Fig.3.10A described a situation in which few genes were highly 
up-regulated, but a lot had a significant p-value. The red line represents the cut-off 
line we decided to use for the screening of our candidates, considering the ones 
with p-value higher than 0.001. We used software analysis tools from Ingenuity 
(IPA) as well as from the Broad Institute (GSEA) and in both ways the pathway 
analyses underlined a strong involvement of the immune system in the UV 
response. Pathways involving B and T cells were in fact the first ones suggested 
by these tools. Further analyses performed with the help of bioinformatics helped 
us clarifying the up- and down-regulated pathways, comparing our data with 
different databases like KEGG, REACTOME, GENE ONTHOLOGY and 
BIOCARTA. The data obtained from the enrichment analysis suggested that 
KEGG was the most suitable database to refer to, and the node-edge diagram 
(Fig.3.11) allowed us to easily identify up- and down-regulated pathways. In 
particular we focused our attention on pathways related to amino acids 
metabolism. As shown in Fig 3.11A, tryptophan and amino-nucleotide sugar 
pathways were up-regulated, while the degradation of small amino acids like 
Valine, Leucine and Isoleucin was down-regulated. Interstingly, also selenoamino 
acid metabolism was down-regulated. All together, these data are representative 
of a metabolic situation in the UV irradiated cells where the mainly promoted 
function is cell survival. In fact, instead of degrading small amino acids in response 
to critical situations, sugars are utilized. Also protein synthesis is decreased in this 
stress setting, due to other priorities of the cells. The same situation could be 
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described from Fig.3.11B, where there was an up-regulation of the homologous 
recombination pathway in order to repair DNA damages and a down-regulation of 
the ribosome complex, where proteins were no longer produced due to a cell cycle 
arrest. As explained by Rudra and Warner in their studies in yeast (109), ribosome 
synthesis is a massive consumer within the economy of the cell, since it requires 
several elements working together. The same is true for any other organism. In 
case of amino acid deprivation or stress caused by diverse sources, including heat 
shock, free radicals or radiation, repression of ribosome synthesis can occur. This 
is reflected by the down-regulation of the mTOR pathway in irradiated cells. Also 
other studies performed in vitro described the complexity of the transcriptional 
profile of the UVB response. In fact, keratinocytes respond by enhancing 
processes involved in energy production and translation, while suppressing those 
related to transcription, differentiation and transport. This response can vary 
depending on the time passed between posing the stress factor and collecting the 
samples, since the cells require some time to activate the repairing mechanisms. 
Further, seemingly paradoxical, genes that were up- or down-regulated after the 
UVB dose can demonstrate an opposing direction of regulation if measured at a 
later time point, reflecting the recovery of UVB-damaged cellular activities (110, 
111). Interestingly, another study performed in lymphoblastoid human cells 
revealed that most genes responded to UV, but with less than 2-fold change 
compared to untreated conditions, similar to the situation we found in our mice. 
Furthermore, not only damage-response pathways were found, but also several 
metabolism-related pathways which were not previously associated with the 
damage response in mammals, but conserved in yeast (112). 
The model we want to propose is explained here below (Fig. 4.2). UVB irradiation 
has been proved to be beneficial for treatment of EAE in mice. On the skin 
surface, metabolites like inosine are produced and are able to activate the AhR 
present on skin APCs like DCs and LCs. These cells do not lose their ability to 
migrate to the draining LNs, but they bring along the activating signals necessary 
for priming cells in LNs as well as the “danger” message generated by the 
irradiation. Once there, they can induce UV-Tregs, inhibiting TH17 immune response 
and they can also activate the response cascade necessary to repair DNA 
damages. 
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Figure 4.2 Proposed mechanism of UVB induced immune regulation in EAE. AhR on DCs is 
activated by products generated from UVB irradiation, like inosine. Activated DCs migrate to LNs 
and activate UV-Tregs, inhibiting TH17 immune response (Revised from Lisa A. DeLouise,  
Engineering Smart Bandage Bio Nanomaterials for Healing Skin). 
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4.2 Project 2: Teriflunomide metabolism is dependent on the aryl 
hydrocarbon receptor 
 
In the present study, we identified a new mechanism, where the aryl hydrocarbon 
receptor plays an essential role in metabolizing the drug Teriflunomide. AhR is a 
cytoplasmatic receptor known for mediating the response to xenobiotic and toxins, 
but emerging research also highlighted its role in modulating lymphocytic immune 
responses in the context of neuroinflammation, brain tumour immunology and 
inflammatory tolerance (113-117). Our group and others have identified the 
tryptophan metabolite kynurenine, produced in brain tumour cells via the rate-
limiting enzyme tryptophan-2,3-dioxygenase, as an endogenous ligand for the 
AhR, promoting tumour growth and invasiveness as well as immune escape (114, 
115). In the MS context, its role has been widely described as mediator of T cell 
differentiation (116, 117). The AhR can be activated by a variety of structurally 
unrelated compounds like the xenobiotics benzo[a]pyrene and 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) or the endogenous tryptophan photoproduct 
6-formylindolo (3,2-b)carbazole (FICZ), which elicited different responses and 
effects (118).  
On the other side, Teriflunomide is a non-competitive inhibitor of the mitochondrial 
enzyme dihydroorotate-dehydrogenase (DHODH), recently approved for MS 
treatment, due to its effect on blocking de novo pyrimidine synthesis and 
interfering in T and B immune cell proliferation. Ringheim et al. showed that TER 
attenuates immunopatological changes in the rat model of EAE, delaying the onset 
of the disease significantly (12). 
A possible interaction between AhR and TER has also been considered. 
O’Donnell et al. showed in human and mouse hepatoma cell lines that 
leflunomide, but not its active metabolite TER would bind and activate the AhR. 
Using primary T cell cultures from WT and AhR deficient mice (AhR-/-), they 
showed that AhR is negligible for leflunomide and TER mediated inhibition of 
proliferation (119). Baban et al., using a mouse model of ischemic renal failure, 
showed an induction of regulatory T helper cells (Treg) and a reduction of pro-
inflammatory IL-17 producing T helper cells (TH17), due to the AhR activation 
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mediated by leflunomide (120). These data remain speculative as both studies 
lacked the use of AhR-/- mice, not giving any information regarding any AhR-
dependent metabolization and toxicity of TER. 
Therefore, our goal was to study the interaction between the two of them, 
comparing deficient and proficient AhR mice in a MS context. The first step was to 
confirm what was shown by Ringheim et al. Immunised mice were daily treated 
with TER and control treatment during the course of the experiment, control 
groups developed the classical EAE immunopatological changes, while the TER 
groups had a significant delayed onset of the disease. This result demonstrated 
that the AhR was not a key molecule in the immunosuppressive mechanism of 
TER. However, AhR-/- mice lost significantly more weight and died upon TER 
treatment. As shown in Fig 3.13, macroscopic investigation showed that this 
correlated with a dark colour on the intestine of the mice. Histological analyses 
were then performed to identify the cause of death, which was attributed to a 
bleeding on the small intestine, or to an inflammation and brake of the intestinal 
barrier. All the other organs analysed resulted in a regular morphology. To support 
the histological analyses, blood tests were also performed. No significant 
differences were found in Hemoglobin levels nor in red or white cell counts, but 
there was a significant decrease of thrombocytes in TER-treated mice. This 
correlated with the clinical trial tests, where lower thrombocyte counts were 
present in the blood of TER treated patients. Tests performed on AhR deficient 
mice did not show any developmental problem, nor abnormal features in the 
animals, but a reduced thrombocyte level compared to corresponding wild types 
(121). Therefore we speculated that the administration of TER reduced the counts 
in the AhR-/- mice, possibly inducing a case of thrombocytophenia. Furthermore, 
Alanine aminotransferase (ALT) values and TER levels were measured in the 
mice serum. The first parameter, a marker for acute liver damage, was three times 
elevated in TER treated AhR-/- mice. The second parameter was measured via 
HPLC and accumulated in AhR-/- serum (Fig. 3.14C and D). Clinical trials 
identified liver toxicity as a possible TER side effect in human MS treatment, also 
correlated to the long elimination half-life of TER (122). Our studies stated that the 
accumulation of TER aggravated exponentially liver toxicity in case of AhR 
deficiency.  
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Another important tool used in this study were the DRE-reporter mice. As shown in 
Fig 3.15, their use clearly supported the other results presented before. In fact, 
only in mice treated with TER we detected a luminescent signal, which correlated 
with the AhR activation. Mice were treated every day and imaged every other day. 
The intensity and the amount detected increased over the time, supporting the fact 
that TER accumulation was taking place and it was even necessary to switch on 
the AhR. Another important observation regarded the localization, since the signal 
was not detected on the back of the mice, but only on the front side and 
particularly in organs involved in the metabolic processes. Information from clinical 
trials revealed that TER is cleared by hepatic metabolism and enterohepatic 
circulation (123), it is eliminated unchanged and mainly through bile, specifically 
37.5% is eliminated in the feces and 22.6% in urine. Therefore, we concentrated 
our analyses on liver, gut and kidney, where we detected an up-regulation of 
Cyp1A1 mRNA expression levels. In conclusion, our data showed that an 
interaction between TER and AhR takes place, not to mediate an immune 
response, but as a step in the drug pharmacokinetic. Due to the fundamental role 
of the AhR for an efficient metabolism of TER, genetic AhR variants in MS patients 
might be considered, since they would be relevant to explain undesired side 
effects and toxicity of TER.   
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4.3 Final remarks 
 
This work aimed to analyse the functional role of AhR in the mouse model of MS. 
We were able to show the importance of the AhR as a key molecule in mediating 
the immunosuppressive effect of UVB light as well as the metabolisation of the 
approved MS drug Teriflunomide.  
 
Concerning the first project, further investigations could be performed to delineate 
the bacterial impact on the skin surface. It would be also interesting performing 
measurements of the ATP production in different conditions and deeper analyse 
the structural interaction between inosine and AhR. The mechanism we proposed 
could be further validated, moving into clinical trials, as already shown by Breuer 
et al. (99). A combination of phototherapy and inosine administration could be a 
promising therapy to reduce the degeneration status and the disability of MS 
patients. Moreover, underlying the importance of the AhR in the UVB immune-
response, we believe that genetic tests specific for AhR would be essential for 
clinical purposes and for further pharmacological targeting. 
 
With the Teriflunomide project, we proved once more the functional plasticity of the 
AhR. Further investigation could be performed to verify a possible interaction 
between the drug and AhR also on the immunological side. The identification of 
genetic polymorphisms is again an important parameter to consider for MS 
patients, in order to reduce and prevent side effects. We have to consider that 
TER is currently one of the three FDA-approved oral medications available for the 
treatment of relapsing forms of MS with fingolimod and dimethyl fumarate. While 
injection and IV treatments have proven to be beneficial, these newer oral agents 
also offer positive outcomes for patients. Numerous barriers exist, though, for 
these oral agents, including the unknown long-term efficacy and safety and 
potential side effects. Despite possible side effects, oral agents provide 
convenience, ease of use and the elimination of injection/IV administration-site 
pain. While teriflunomide is no more effective than a number of other agents that 
are used in the treatment of MS, it has the convenience of once a day oral 
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administration. Nevertheless, considering its long half-life and the possible side 
effects during pregnancy, it did not become a popular agent in the treatment of 
MS. The development of new treatments and drugs is such a dynamic process in 
the MS field that more and more compounds will arise in the next years.  
The knowledge of genetic and environmental aspects is fundamental and a 
necessary background for further investigations. Undergoing studies aim to find 
the causes of MS and the factors which determine the disease progression. 
Eventually, doctors will be able to identify people at high risk for the disease and 
intervene with treatment at very early stages of MS, perhaps even before 
symptoms appear. 
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5. Appendix: Generation of a new AhR reporter mouse  
 
5.1 Starting point 
 
The DRE_Luc mice were generated to work in a bilateral way, allowing us to 
detect an AhR activation via luminescent signal (Luciferase) as well as via 
fluorescent one (mCherry). On the contrary, we never managed to detect any 
mCherry signal neither via FACS, nor via staining nor via 2-photon microscope 
imaging. Therefore the generation of a new construct and consequently of a new 
reporter mouse have been an important goal for this laboratory in the last years. 
 
5.2 Monster GFP - a Qiagen helper 
 
Since it has been proved in different ways that the Luciferase signal can be 
detected, we first tried to substitute CGB99 and mCherry with a different 
fluorochrome. We purchased a similar construct, commercially available from 
Qiagen (XRE Reporter), which encodes the Monster GFP gene under the control 
of a minimal (m)CMV promoter and tandem repeats of the XRE transcriptional 
response element (TRE). Therefore, a new construct with the initial 12 x DRE 
repetitions coupled with GFP was created and tested in vitro, using GL261, NIH 
3T3 and Hela cells. Cells were then treated respectively with DMSO or TCDD (10 
nM) 12 h after transfection and imaged in the next 24 h using a confocal 
microscope from the Microscope Core Facility in DKFZ. Unfortunately, the 
background signal detected after control treatment (DMSO) was too high and the 
fluorescence was also less strong than expected (Fig. 5.1B).   
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Figure 5.1. A. Schematic representation of the cloning strategy used in order to test the 12x-GFP 
construct. Briefly, CGB99 luciferase was substituted with a Monster_GFP purchased from Qiagen. 
B. Representative pictures acquired 24 h after treatment, using a Leica TCS SP5 confocal 
microscope. 
 
 
5.3 floxCRe Brainbow – a colourful idea 
 
Due to a high background signal with the Monster_GFP construct, we decided to 
try a flox-cre system. We therefore cloned the DRE repetitions in a vector kindly 
offered by Dr. Feyerabend (Cellular Immunology Dept., DKFZ), which contained a 
iCRE cassette and a stabilizing construct as described elsewhere (124, 125). Cre 
would be stably transcribed only in case of a DRE activation. The flox-plasmid, 
Brainbow-1.0, was a kind gift of Prof. Martin-Villalba (Molecular Neurobiology 
Dept., DKFZ) and it was used to proof Cre functionality. As shown if Fig.5.2A, 
once a Cre-recombinase enzyme cuts the lox sites, cells change their colour from 
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red to either blue or yellow. To verify our work, a co-trasfection with the Brainbow-
1.0 and our new DRE-Cre construct was performed in different cell lines, cells 
were then treated with Kynurenic acid (KYNA) or control (NaOH) and images were 
acquired on a Leica TCS SP5 confocal microscope (Fig.5.2B). 
 
Figure 5.2. Flox-cre strategy. A.. Schematic representation of the Brainbow 1.0 construct and its 
functionality (Addgene- the non profit plasmid repository). On the left, plasmid map of the cre-
plasmid with our additional DRE sequences. B. Pictures of co-transfected cells acquired 24h post 
treatment, using a Leica TCS SP5 confocal microscope.  
 
Also in this case, the cloning procedure worked, we had high transfection efficacy 
(as seen in the untreated control), but a DRE activation and therefore an 
unspecific signal were observed even with control treatment.  
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5.4 Future plans 
 
The generation of a new reported mouse is still a work in progress in our 
laboratory. The complexity of this construct is due to different factors. First, AhR is 
a promiscuous receptor and can be activated by different substances. 
Furthermore, there are a lot of possible variances we can try. Starting from the 
DRE sequences, there is a consensus binding site for the AhR, which is not 
consistently conserved in the DREs constructs available. In order to maintain high 
expression, we also have to pay attention to CpG motifs, which can be methylated 
and thus influence the expression level. Furthermore, promoter, cleavage sites, 
fluorochrome and luciferase can be substituted with different versions of the ones 
already present in the construct. Different collaborations have been established 
with Bayer GmbH and with Dr. Stefan Pusch (Neuropathology Dept., DKFZ) to 
perform in vitro tests. Currently, Dr. Edward Green is working on the optimization 
of the different elements described. In order to move into a murine model, we also 
established a collaboration with Prof. Richard Harbottle, who suggested to use 
Scaffold/Matrix Attachment Region (S/MAR) DNA vectors (126). We could then 
inject the construct into newborn mice and test directly the expression level, before 
generating a new strain. Once the right setup is found, the new mouse line will be 
generated in collaboration with the Animal Laboratory Facility of DKFZ, using the 
new Cas9/CRISPR system (127). 
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List of Abbreviations 
 
 
Ab   Antibody 
ACK   Ammonium-Chloride-Potassium Lysing Buffer 
AhR   Aryl Hydrocarbon Receptor 
ALT   Alanine transaminase  
APC   Allophycocyanin 
APCs    Antigen presenting cells 
ATP    Adenosine triphosphate 
B cell   Bursa of Fabricius-derived lymphocyte 
BBB    Blood-brain-barrier 
CFA   Freund’s adjuvant (CFA) 
CHS   contact hypersensitivity 
CMV   Cytomegalovirus 
CNS    Central nervous system 
ConA   Concanavalin A 
CSF    Cerebrospinal ﬂuid 
Cyp1A1  Cytocrome P 450, family 1, member A1 
DCs    Dendritic cells 
dH2O   Distilled water 
DHODH  Dihydroorotate dehydrogenase 
DMSO  Dimethyl sulfoxide 
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DNA    Deoxyribonucleic acid 
DRE   Dioxin responsive elements 
EAE    Experimental autoimmune encephalomyelitis 
EBV    Epstein-Barr-virus 
EDTA   Ethylenediaminetetraacetic acid 
ELISA   Enzyme Linked Immunosorbent Assay  
FACS   Fluorescence-activated cell sorting 
FBS    Fetal bovine serum 
FDA   Food and Drug Administration 
FICZ   6-Formylindolo(3,2-b)carbazole 
FITC    Fluorescein isothiocyanate 
FoxP3   Forkhead box P3 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GCN2   General control non-derepressible 2 
GFP   Green fluorescent protein 
H2O2    Hydrogen peroxide 
HLA    Human leukocyte antigen 
HPLC   High performance liquid chromatography-mass spectrometry 
i.p.    Intraperitoneal 
IC50   Half maximal inhibitory concentration 
IDO   indoleamine 2,3-dioxygenase 
IFNγ    Interferon-γ 
IL    Interleukin 
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KYNA   Kynurenic Acid 
LCs   Langerhans cells 
LNs   Lymph nodes 
MACS   Magnetic-activated cell sorting 
MBP    Myelin basic protein 
MC   Methylcellulose 
MHC   Major histocompatibility complex 
MOG    Myelin oligodendrocyte glycoprotein 
MRI   magnetic resonance imaging 
MS    Multiple sclerosis 
NAD+   Nicotinamide adenine dinucleotide 
NaOH   Sodium hydroxide 
NK    Natural killer 
o/n    Overnight 
p.i.    Post-immunisation 
PBS    Phosphate-buﬀered saline 
PCR    Polymerase chain reaction 
PE    Phycoerythrin 
PerCP   Peridinin chlorophyll protein 
PLP    Proteolipid protein 
PPMS   Primary-progressive MS 
PRMS  Progressive-relapsing MS 
PToX    Pertussis toxin 
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RNA    Ribonucleic acid 
ROI   Region of Interest 
RPMI    Roswell Park Memorial Institute 
RRMS   Relapsing-remitting multiple sclerosis 
s.c.    Subcutaneous 
S.E.M.   Standard error of the mean 
SLE    Systemic lupus erythematosus 
SPMS   Secondary progressive MS 
T cell    Thymus-derived lymphocyte 
TCDD   2,3,7,8-Tetrachlorodibenzo-p-dioxin 
TCR   T cell receptor 
TDO    Tryptophan dioxygenase 
TER    Teriflunomide 
TER   Teriflunomide 
TGFα    Transforming growth factor-α 
TGFβ    Transforming growth factor-β 
TH0    Naïve CD4+ T cells 
TH1   T helper type 1 
TH17   T helper type 17 
TMEV   Theiler’s Murine Encephalomyelitis Virus 
TNFα    Tumour necrosis factor-α 
Treg(s)    Regulatory T cell(s) 
tRNA    Transfer ribonucleic acid 
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Trp   Tryptophan 
UV(B)   Ultraviolet radiation type B 
wt    Wild-type 
